0001104659-16-154583.txt : 20161103 0001104659-16-154583.hdr.sgml : 20161103 20161103162645 ACCESSION NUMBER: 0001104659-16-154583 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161103 DATE AS OF CHANGE: 20161103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 161971998 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD STREET 2: D-322 AP6D CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 8479376100 10-Q 1 a16-17215_110q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 1-2189

ABBOTT LABORATORIES

An Illinois Corporation				I.R.S. Employer Identification No.
				36-0698440

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

Telephone: (224) 667-6100

Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer x		Accelerated Filer o

Non-Accelerated Filer o		Smaller reporting company o
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of September 30, 2016, Abbott Laboratories had 1,472,309,523 common shares without par value outstanding.

Table of Contents

Abbott Laboratories

Table of Contents

	Page

Part I - Financial Information

Item 1. Financial Statements and Supplementary Data

Condensed Consolidated Statement of Earnings	3
Condensed Consolidated Statement of Comprehensive Income	4
Condensed Consolidated Balance Sheet	5
Condensed Consolidated Statement of Cash Flows	6
Notes to the Condensed Consolidated Financial Statements	7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	20

Item 3. Quantitative and Qualitative Disclosures about Market Risk	27

Item 4. Controls and Procedures	27

Part II - Other Information

Item 1. Legal Proceedings	27

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	28

Item 6. Exhibits	28

Signature	29

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited)

(dollars in millions except per share data; shares in thousands)

	Three Months Ended						Nine Months Ended
	September 30						September 30
	2016			2015			2016			2015
Net sales	$	5,302		$	5,150		$	15,520		$	15,217

Cost of products sold, excluding amortization of intangible assets	2,285			2,242			6,712			6,541
Amortization of intangible assets	140			151			429			458
Research and development	352			378			1,079			1,036
Selling, general and administrative	1,628			1,666			5,063			5,130
Total operating cost and expenses	4,405			4,437			13,283			13,165

Operating earnings	897			713			2,237			2,052

Interest expense	117			41			278			122
Interest (income)	(22		)	(25		)	(75		)	(73		)
Net foreign exchange loss (gain)	9			(14		)	497			(63		)
Other expense (income), net	972			(3		)	999			(287		)
Earnings (loss) from continuing operations before taxes	(179		)	714			538			2,353
Taxes on earnings (loss) from continuing operations	178			118			240			442
Earnings (loss) from continuing operations	(357		)	596			298			1,911

Earnings (loss) from discontinued operations, net of tax	28			(32		)	288			(7		)
Gain (loss) on sale of discontinued operations, net of tax	—			16			16			1,752
Net earnings (loss) from discontinued operations, net of tax	28			(16		)	304			1,745
Net earnings (loss)	$	(329	)	$	580		$	602		$	3,656

Basic Earnings (Loss) Per Common Share —
Continuing operations	$	(0.24	)	$	0.40		$	0.20		$	1.27
Discontinued operations	0.02			(0.01		)	0.21			1.16
Net earnings (loss)	$	(0.22	)	$	0.39		$	0.41		$	2.43

Diluted Earnings (Loss) Per Common Share —
Continuing operations	$	(0.24	)	$	0.39		$	0.20		$	1.26
Discontinued operations	0.02			(0.01		)	0.20			1.15
Net earnings (loss)	$	(0.22	)	$	0.38		$	0.40		$	2.41

Cash Dividends Declared Per Common Share	$	0.26		$	0.24		$	0.78		$	0.72

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share	1,476,366			1,495,465			1,476,351			1,498,914
Dilutive Common Stock Options	—			9,702			6,329			10,230

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	1,476,366			1,505,167			1,482,680			1,509,144

Outstanding Common Stock Options Having No Dilutive Effect	12,103			717			5,445			658

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Comprehensive Income

(Unaudited)

(dollars in millions)

	Three Months Ended						Nine Months Ended
	September 30						September 30
	2016			2015			2016			2015
Net Earnings (loss)	$	(329	)	$	580		$	602		$	3,656
Foreign currency translation (loss) gain adjustments	89			(645		)	406			(1,472		)
Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $8 and $5 in 2016 and $14 and $39 in 2015	15			26			(14		)	79
Unrealized gains (losses) on marketable equity securities, net of taxes of $(28) and $(28) in 2016 and $(240) and $104 in 2015	613			(1,596		)	(143		)	(901		)
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $(7) and $(31) in 2016 and $2 and $2 in 2015	(27		)	8			(124		)	9
Other comprehensive income (loss)	690			(2,207		)	125			(2,285		)
Comprehensive income (loss)	$	361		$	(1,627	)	$	727		$	1,371

	Sept. 30, 2016			December 31, 2015
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments	$	(4,423	)	$	(4,829	)
Net actuarial (losses) and prior service cost and credits	(1,972		)	(1,958		)
Cumulative unrealized (losses) gains on marketable equity securities	(78		)	65
Cumulative (losses) gains on derivative instruments designated as cash flow hedges and other	(60		)	64

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Balance Sheet

(Unaudited)

(dollars in millions)

	September 30, 2016			December 31, 2015
Assets
Current Assets:
Cash and cash equivalents	$	2,500		$	5,001
Short-term investments	2,007			1,124
Trade receivables, less allowances of $284 in 2016 and $337 in 2015	3,320			3,418
Inventories:
Finished products	1,763			1,744
Work in process	326			316
Materials	524			539
Total inventories	2,613			2,599
Prepaid expenses and other receivables	1,986			1,908
Current assets held for disposition	552			105
Total Current Assets	12,978			14,155
Investments	2,997			4,041
Property and equipment, at cost	12,452			12,383
Less: accumulated depreciation and amortization	6,718			6,653
Net property and equipment	5,734			5,730
Intangible assets, net of amortization	4,674			5,562
Goodwill	7,812			9,638
Deferred income taxes and other assets	2,523			2,119
Non-current assets held for disposition	2,779			2
	$	39,497		$	41,247
Liabilities and Shareholders’ Investment
Current Liabilities:
Short-term borrowings	$	2,531		$	3,127
Trade accounts payable	1,051			1,081
Salaries, wages and commissions	799			746
Other accrued liabilities	2,715			3,043
Dividends payable	384			383
Income taxes payable	240			430
Current portion of long-term debt	4			3
Current liabilities held for disposition	597			373
Total Current Liabilities	8,321			9,186
Long-term debt	5,975			5,871
Post-employment obligations, deferred income taxes and other long-term liabilities	4,245			4,864
Non-current liabilities held for disposition	60			—
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued	—			—
Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2016: 1,706,957,661; 2015: 1,702,017,390	12,939			12,734
Common shares held in treasury, at cost — Shares: 2016: 234,648,138; 2015: 229,352,338	(10,792		)	(10,622		)
Earnings employed in the business	25,162			25,757
Accumulated other comprehensive income (loss)	(6,533		)	(6,658		)
Total Abbott Shareholders’ Investment	20,776			21,211
Noncontrolling Interests in Subsidiaries	120			115
Total Shareholders’ Investment	20,896			21,326
	$	39,497		$	41,247

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Cash Flows

(Unaudited)

(dollars in millions)

	Nine Months Ended September 30
	2016			2015
Cash Flow From (Used in) Operating Activities:
Net earnings	$	602		$	3,656
Adjustments to reconcile net earnings to net cash from operating activities -
Depreciation	605			648
Amortization of intangible assets	429			458
Share-based compensation	263			249
Impact of currency devaluation	481			—
Gain on sale of discontinued operations	(25		)	(2,837		)
Mylan N.V. equity investment adjustment	947			—
Gain on sale of Mylan N.V. shares	—			(207		)
Trade receivables	(116		)	(151		)
Inventories	(152		)	(213		)
Other, net	(1,001		)	535
Net Cash From Operating Activities	2,033			2,138

Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment	(802		)	(862		)
Proceeds from business disposition	25			230
Acquisitions of businesses and technologies, net of cash acquired	(73		)	(235		)
Proceeds from the sale of Mylan N.V. shares	—			2,290
Sales (Purchases) of other investment securities, net	(982		)	(2,626		)
Other	34			43
Net Cash (Used in) Investing Activities	(1,798		)	(1,160		)

Cash Flow From (Used in) Financing Activities:
Net (repayments of) proceeds from issuance of short-term debt and other	(682		)	(2,019		)
Proceeds from the issuance of long-term debt	—			2,485
Repayments of long-term debt	(11		)	(36		)
Payment of debt issuance costs	(170		)	—
Payment of contingent consideration	(25		)	—
Purchases of common shares	(522		)	(1,349		)
Proceeds from stock options exercised, including income tax benefit	206			263
Dividends paid	(1,153		)	(1,083		)
Net Cash (Used in) Financing Activities	(2,357		)	(1,739		)

Effect of exchange rate changes on cash and cash equivalents	(379		)	(170		)

Net Decrease in Cash and Cash Equivalents	(2,501		)	(931		)
Cash and Cash Equivalents, Beginning of Year	5,001			4,063
Cash and Cash Equivalents, End of Period	$	2,500		$	3,132

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

September 30, 2016

(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2015. The consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

Note 2 — Discontinued Operations

On February 27, 2015, Abbott completed the sale of its developed markets branded generics pharmaceuticals business to Mylan Inc. (Mylan) for 110 million shares (or approximately 22%) of a newly formed entity (Mylan N.V.) that combined Mylan’s existing business and Abbott’s developed markets branded generics pharmaceuticals business. Mylan N.V. is publicly traded. Historically, this business was included in Abbott’s Established Pharmaceutical Products segment. Abbott retained its branded generics pharmaceuticals business in emerging markets. At the date of closing, the 110 million Mylan N.V. shares that Abbott received were valued at $5.77 billion and Abbott recorded an after-tax gain on the sale of the business of approximately $1.6 billion. The shareholder agreement with Mylan N.V. includes voting and other restrictions that prevent Abbott from exercising significant influence over the operating and financial policies of Mylan N.V.

At the close of this transaction, Abbott and Mylan entered into a transition services agreement pursuant to which Abbott and Mylan are providing various back office support services to each other on an interim transitional basis. Transition services may be provided for up to 2 years. Charges by Abbott under this transition services agreement are recorded as a reduction of the costs to provide the respective service in the applicable expense category in the Condensed Consolidated Statement of Earnings. This transition support does not constitute significant continuing involvement in Mylan’s operations. Abbott also entered into manufacturing supply agreements with Mylan related to certain products, with the supply term ranging from 3 to 10 years and requiring a 2 year notice prior to termination. The cash flows associated with these transition services and manufacturing supply agreements are not expected to be significant, and therefore, these cash flows are not direct cash flows of the disposed component under Accounting Standards Codification 205.

In April 2015, Abbott sold 40.25 million of the 110 million ordinary shares of Mylan N.V. received in the sale of the developed markets branded generics pharmaceuticals business to Mylan. In the second quarter of 2015, Abbott recorded a pretax gain of $207 million on $2.29 billion in net proceeds from the sale of these shares. The gain was recognized in the Other (income) expense line of the Condensed Consolidated Statement of Earnings. As a result of this sale, Abbott’s ownership interest in Mylan N.V. decreased to approximately 14%.

On February 10, 2015, Abbott completed the sale of its animal health business to Zoetis Inc. Abbott received cash proceeds of $230 million and reported an after-tax gain on the sale of approximately $130 million in the first quarter of 2015. In the first quarter of 2016, Abbott received an additional $25 million of proceeds related to the expiration of a holdback agreement associated with the sale of this business and reported an after-tax gain on the sale of discontinued operations of $16 million.

As a result of the disposition of the above businesses, the operating results of these businesses up to the date of sale are reported as part of discontinued operations on the Earnings from Discontinued Operations, net of tax line in the Condensed Consolidated Statement of Earnings. The cash flows associated with the developed markets branded generics pharmaceuticals and animal health businesses up to the date of disposition are included in Abbott’s Condensed Consolidated Statement of Cash Flows.

On January 1, 2013, Abbott completed the separation of AbbVie Inc. (AbbVie), which was formed to hold Abbott’s research-based proprietary pharmaceuticals business. For a small portion of AbbVie’s operations, the legal transfer of AbbVie’s assets (net of liabilities) did not occur with the separation of AbbVie on January 1, 2013 due to the time required to transfer marketing authorizations and other regulatory requirements in each of these countries. Under the terms of the separation agreement with Abbott, AbbVie is subject to the risks and entitled to the benefits generated by these operations and assets. The majority of these operations were transferred to AbbVie in 2013 and 2014. These assets and liabilities have been presented as held for disposition in the

Table of Contents

Condensed Consolidated Balance Sheet. Abbott has recorded a prepaid asset of $306 million for its obligation to transfer these net liabilities held for disposition to AbbVie.

Abbott has retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation, as well as certain non-income related taxes attributable to AbbVie’s business prior to the separation. AbbVie generally will be liable for all other taxes attributable to its business. Net earnings from discontinued operations in the first nine months of 2016 and 2015 reflect the recognition of $282 million of tax benefit and $10 million of tax expense, respectively, as a result of the resolution of various tax positions related to AbbVie’s operations for years prior to the separation.

The following table summarizes the components of discontinued operations:

	Three Months Ended Sept. 30						Nine Months Ended Sept. 30
(in millions)	2016			2015			2016			2015
Net Sales
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	—		$	—		$	256
AbbVie	—			—			—			—
Total	$	—		$	—		$	—		$	256
Earnings (Loss) Before Tax
Developed markets generics pharmaceuticals and animal health businesses	$	5		$	(6	)	$	(1	)	$	14
AbbVie	—			—			—			—
Total	$	5		$	(6	)	$	(1	)	$	14
Income Tax Expense (Benefit)
Developed markets generics pharmaceuticals and animal health businesses	$	(4	)	$	(1	)	$	(7	)	$	11
AbbVie	(19		)	27			(282		)	10
Total	$	(23	)	$	26		$	(289	)	$	21
Net Earnings (Loss)
Developed markets generics pharmaceuticals and animal health businesses	$	9		$	(5	)	$	6		$	3
AbbVie	19			(27		)	282			(10		)
Total	$	28		$	(32	)	$	288		$	(7	)

The sale of the developed markets branded generics pharmaceuticals and animal health businesses in the first nine months of 2015 resulted in the recognition of a pretax gain of $2.837 billion, tax expense of $1.085 billion and an after-tax gain of $1.752 billion.

Note 3 — Assets and Liabilities Held for Disposition

In September 2016, Abbott announced that it will sell Abbott Medical Optics (AMO), its vision care business, to Johnson & Johnson for $4.325 billion in cash. The decision to sell AMO reflects Abbott’s proactive shaping of its portfolio in line with its strategic priorities. The transaction is expected to close in the first quarter of 2017 and is subject to customary closing conditions, including regulatory approvals. The operating results of AMO do not qualify for reporting as discontinued operations. For the three months ended September 30, 2016 and 2015, AMO’s earnings (loss) before taxes were $2 million and $(2) million, respectively. For the first nine months ended September 30, 2016 and 2015, AMO’s earnings (loss) before taxes were $(42) million and $54 million, respectively. As a result of the planned sale of AMO, the assets and liabilities of this business meet the criteria to qualify as being held for disposition at September 30, 2016.

The assets and liabilities held for disposition as of September 30, 2016 relate to the AMO and AbbVie businesses. The assets and liabilities held for disposition as of December 31, 2015 relate to the AbbVie business.

Table of Contents

The following is a summary of the assets and liabilities held for disposition:

(in millions)	September 30, 2016		December 31, 2015
Trade receivables, net	$	226	$	17
Total inventories	247		43
Prepaid expenses and other current assets	79		45
Current assets held for disposition	552		105
Net property and equipment	238		1
Intangible assets, net of amortization	533		—
Goodwill	1,986		—
Deferred income taxes and other assets	22		1
Non-current assets held for disposition	2,779		2
Total assets held for disposition	$	3,331	$	107

Trade accounts payable	$	421	$	359
Salaries, wages, commissions and other accrued liabilities	176		14
Current liabilities held for disposition	597		373
Post-employment obligations, deferred income taxes and other long-term liabilities	60		—
Total liabilities held for disposition	$	657	$	373

Note 4 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings (loss) from Continuing Operations allocated to common shares for the three months ended September 30, 2016 and 2015 were $(357) million and $593 million, respectively, and for the nine months ended September 30, 2016 and 2015 were $297 million and $1.902 billion, respectively. Net earnings (loss) allocated to common shares for the three months ended September 30, 2016 and 2015 were $(329) million and $577 million, respectively, and for the nine months ended September 30, 2016 and 2015 were $600 million and $3.638 billion, respectively.

On September 30, 2016, Abbott recorded expense of $947 million to adjust its holding of Mylan N.V. ordinary shares due to a decline in the fair value of the securities which is considered by Abbott to be other than temporary. The adjustment reflects Mylan N.V.’s share price as of September 30, 2016 and is included in the Other expense (income), net line of the Condensed Consolidated Statement of Earnings.

In the first nine months of 2015, Other (income) expense, net primarily relates to a $207 million gain on the sale of a portion of Abbott’s position in Mylan N.V. stock and $79 million of income resulting from a decrease in the fair value of contingent consideration related to a business acquisition. In the first nine months of 2015, Abbott sold 40.25 million of the 110 million ordinary shares of Mylan N.V. received in the sale of the developed markets branded generics pharmaceuticals business to Mylan. Abbott received $2.29 billion in net proceeds from the sale of these shares. As a result of this sale, Abbott’s ownership interest in Mylan N.V. decreased from approximately 22% to approximately 14%.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2016 and 2015 includes the effects of contributions to defined benefit plans of $540 million and $551 million, respectively, and to the post-employment medical and dental benefit plans of $9 million and $24 million, respectively. The first nine months of 2016 also includes the non-cash impact of approximately $539 million of net tax benefits primarily associated with the resolution of various tax positions from prior years, as well as cash taxes paid of approximately $140 million related to the disposition of businesses. The first nine months of 2015 includes the non-cash impact of approximately $1.1 billion of tax expense associated with the gain on the sale of businesses. The foreign currency loss related to Venezuela in the first nine months of 2016 reduced Abbott’s cash by approximately $410 million and is shown on the Effect of exchange rate changes on cash and cash equivalents line within the Condensed Consolidated Statement of Cash Flows.

Since January 2010, Venezuela has been designated as a highly inflationary economy under U.S. GAAP. In 2014 and 2015, the government of Venezuela operated multiple mechanisms to exchange bolivars into U.S. dollars. These mechanisms included the CENCOEX, SICAD, and SIMADI rates, which stood at 6.3, 13.5, and approximately 200, respectively, at December 31, 2015. In 2015, Abbott continued to use the CENCOEX rate of 6.3 Venezuelan bolivars to the U.S. dollar to report the results, financial

Table of Contents

position, and cash flows related to its operations in Venezuela since Abbott continued to qualify for this exchange rate to pay for the import of various products into Venezuela.

On February 17, 2016, the Venezuelan government announced that the three-tier exchange rate system would be reduced to two rates renamed the DIPRO and DICOM rates. The DIPRO rate is the official rate for food and medicine imports and was adjusted from 6.3 to 10 bolivars per U.S. dollar. The DICOM rate is a floating market rate published daily by the Venezuelan central bank, which at the end of the first quarter of 2016 was approximately 263 bolivars per U.S. dollar. As a result of decreasing government approvals to convert bolivars to U.S. dollars to pay for intercompany accounts, as well as the accelerating deterioration of economic conditions in the country, Abbott concluded that it was appropriate to move to the DICOM rate at the end of the first quarter of 2016. As a result, Abbott recorded a foreign currency loss of $481 million in the first nine months of 2016 to revalue its net monetary assets in Venezuela. Abbott is continuing to use the DICOM rate to report the results of operations and to remeasure net monetary assets for Venezuela at the end of each quarter. As of September 30, 2016, Abbott’s Venezuelan operations represented approximately 0.1% of Abbott’s consolidated assets and any additional foreign currency losses related to Venezuela are not expected to be material.

The components of long-term investments as of September 30, 2016 and December 31, 2015 are as follows:

(in millions)	September 30,		December 31,
Long-term Investments	2016		2015
Equity securities	$	2,946	$	4,014
Other	51		27
Total	$	2,997	$	4,041

Table of Contents

Note 5 — Changes in Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

	Three Months Ended September 30
	Cumulative Foreign Currency Translation Adjustments						Net Actuarial Losses and Prior Service Costs and Credits						Cumulative Unrealized Gains (Losses) on Marketable Equity Securities						Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
(in millions)	2016			2015			2016			2015			2016			2015			2016			2015
Balance at June 30	$	(4,512	)	$	(3,643	)	$	(1,987	)	$	(2,157	)	$	(691	)	$	696		$	(33	)	$	100
Other comprehensive income (loss) before reclassifications	89			(645		)	—			—			(362		)	(1,596		)	(30		)	41
Amounts reclassified from accumulated other comprehensive income (loss)	—			—			15			26			975			—			3			(33		)
Net current period comprehensive income (loss)	89			(645		)	15			26			613			(1,596		)	(27		)	8
Balance at September 30	$	(4,423	)	$	(4,288	)	$	(1,972	)	$	(2,131	)	$	(78	)	$	(900	)	$	(60	)	$	108

	Nine Months Ended September 30
	Cumulative Foreign Currency Translation Adjustments						Net Actuarial Losses and Prior Service Costs and Credits						Cumulative Unrealized Gains (Losses) on Marketable Equity Securities						Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
(in millions)	2016			2015			2016			2015			2016			2015			2016			2015
Balance at December 31, 2015 and 2014	$	(4,829	)	$	(2,924	)	$	(1,958	)	$	(2,229	)	$	65		$	1		$	64		$	99
Impact of business dispositions	—			108			—			19			—			—			—			—
Other comprehensive income (loss) before reclassifications	406			(1,472		)	(62		)	—			(1,118		)	(763		)	(77		)	89
Amounts reclassified from accumulated other comprehensive income (loss)	—			—			48			79			975			(138		)	(47		)	(80		)
Net current period comprehensive income (loss)	406			(1,472		)	(14		)	79			(143		)	(901		)	(124		)	9
Balance at September 30	$	(4,423	)	$	(4,288	)	$	(1,972	)	$	(2,131	)	$	(78	)	$	(900	)	$	(60	)	$	108

Reclassified amounts for foreign currency translation are recorded in the Condensed Consolidated Statement of Earnings as Net foreign exchange loss (gain); gains (losses) on marketable equity securities as Other (income) expense, net and cash flow hedges as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit plan costs; see Note 12 for additional details.

Table of Contents

Note 6 — Business Acquisitions

In August 2015, Abbott completed the acquisition of the equity of Tendyne Holdings, Inc. (Tendyne) that Abbott did not already own for approximately $225 million in cash plus additional payments up to $150 million to be made upon completion of certain regulatory milestones. The acquisition of Tendyne, which is focused on developing minimally invasive mitral valve replacement therapies, allows Abbott to broaden its foundation in the treatment of mitral valve disease. The final allocation of the fair value of the acquisition resulted in non-deductible acquired in-process research and development of approximately $220 million, which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation, non-deductible goodwill of approximately $142 million, deferred tax assets and other net assets of approximately $18 million, deferred tax liabilities of approximately $85 million, and contingent consideration of approximately $70 million. The goodwill is identifiable to the Vascular Products segment. Had this acquisition taken place as of the beginning of the comparable prior annual reporting period, consolidated net sales and earnings would not have been significantly different from reported amounts.

On January 30, 2016, Abbott entered into a definitive agreement to acquire Alere Inc. (Alere). With annual sales of approximately $2.5 billion, Alere is a global leader in point of care diagnostics. The acquisition, which is expected to significantly advance Abbott’s global diagnostics presence and leadership, is subject to the approval of Alere shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. On May 2, 2016, Abbott and Alere received a request for additional information from the United States Federal Trade Commission (FTC) relating to Abbott’s potential acquisition of Alere. The effect of this request, which was issued under the Hart-Scott Rodino (HSR) Antitrust Improvements Act of 1976, as amended, is to extend the waiting period imposed by the HSR Act until 30 days after Abbott and Alere have substantially complied with this request, unless the period is extended voluntarily by the parties or terminated sooner by the FTC.

On August 25, 2016, Alere filed a lawsuit against Abbott alleging that Abbott had breached its obligations under the agreement in connection with obtaining regulatory approvals. Abbott denies Alere’s allegations in the case. Abbott has complied with all of its obligations under the agreement.

On October 21, 2016, Alere shareholders approved the acquisition.

Under the terms of the agreement, Abbott will pay $56 per common share at a total expected equity value of $5.8 billion. Alere’s net debt, currently $2.5 billion, will be assumed or refinanced by Abbott. In February 2016, Abbott obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed $9 billion in conjunction with its pending acquisition of Alere. While Abbott plans to use cash on hand at the time of the acquisition from anticipated long-term borrowings to acquire Alere, the bridge facility will provide back-up financing.

On April 27, 2016, Abbott entered into a definitive agreement to acquire St. Jude Medical, Inc. (St. Jude Medical). With 2015 sales of approximately $5.5 billion, St. Jude Medical is a global medical device manufacturer. The acquisition, which is expected to significantly advance Abbott’s global cardiovascular device presence and leadership, is subject to the approval of St. Jude Medical shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. On July 11, 2016, Abbott and St. Jude Medical received a request for additional information from the FTC relating to Abbott’s potential acquisition of St. Jude Medical. The effect of this request, which was issued under the HSR Act, is to extend the waiting period imposed by the HSR Act until 30 days after Abbott and St. Jude Medical have substantially complied with this request, unless the period is extended voluntarily by the parties or terminated sooner by the FTC. On October 18, 2016, Abbott and St. Jude Medical announced an agreement to sell certain products to Terumo Corporation (Terumo). The transaction with Terumo reflects a purchase price of approximately $1.12 billion and is subject to the successful completion of Abbott’s acquisition of St. Jude Medical and antitrust regulatory approvals.

On October 26, 2016, St. Jude Medical shareholders approved the acquisition.

Under the terms of the agreement, for each share of stock, St. Jude Medical shareholders will receive $46.75 in cash and 0.8708 of a share of Abbott common stock. At an Abbott stock price of $40.74, which reflects the closing price on October 20, 2016, this represents a value of approximately $82 per common share at a total expected equity value of approximately $24 billion. St. Jude Medical’s net debt of approximately $5.4 billion will be assumed or refinanced by Abbott. In April 2016, Abbott obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed $17.2 billion in conjunction with its pending acquisition of St. Jude Medical. While Abbott plans to fund the cash portion of this transaction with anticipated medium and long-term borrowings, the bridge facility will provide back-up financing.

Table of Contents

Note 7 — Goodwill and Intangible Assets

The total amount of goodwill reported was $7.812 billion at September 30, 2016 and $9.638 billion at December 31, 2015. The amount at September 30, 2016 excludes goodwill included in non-current assets held for disposition. In the third quarter of 2016, approximately $2.0 billion of goodwill was moved to Non-current assets held for disposition due to the pending sale of AMO. In the first nine months of 2016, foreign currency translation adjustments increased goodwill by approximately $126 million. There were no purchase price allocation adjustments associated with recent acquisitions made during the nine months of 2016. The amount of goodwill related to reportable segments at September 30, 2016 was $3.0 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $451 million for the Diagnostic Products segment, and $3.1 billion for the Vascular Products segment. There was no reduction of goodwill relating to impairments.

The gross amount of amortizable intangible assets, primarily product rights and technology was $10.5 billion as of September 30, 2016 and $10.8 billion as of December 31, 2015, and accumulated amortization was $6.1 billion as of September 30, 2016 and $5.7 billion as of December 31, 2015. The September 30, 2016 amounts exclude the intangibles included in Non-current assets held for disposition. In the third quarter of 2016, approximately $533 million of net intangible assets related to AMO was moved to Non-current assets held for disposition due to the pending sale of this business. Foreign currency translation adjustments increased intangible assets by $72 million in the first nine months of 2016. Indefinite-lived intangible assets, which relate to in-process research and development acquired in a business combination, were approximately $325 million and $419 million as of September 30, 2016 and December 31, 2015, respectively. In the first nine months of 2016, Abbott recorded an impairment of a $59 million in-process research and development project related to a non-reportable segment. Abbott’s estimated annual amortization expense for intangible assets is approximately $560 million in 2016, $490 million in 2017, $450 million in 2018, $420 million in 2019 and $410 million in 2020. Amortizable intangible assets are amortized over 2 to 20 years (weighted average 13 years).

Note 8 — Restructuring Plans

In 2016, 2015 and 2014, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses. In the first nine months of 2016, charges of approximately $23 million were recognized, of which approximately $7 million is recognized as Cost of products sold and approximately $16 million as Selling, general and administrative expense. Additional charges of approximately $2 million were recorded primarily for accelerated depreciation. The following summarizes the activity for the first nine months of 2016 related to these restructuring actions and the status of the related accrual as of September 30, 2016:

(in millions)
Accrued balance at December 31, 2015	$	100
Restructuring charges recorded in 2016	23
Payments and other adjustments	(47		)
Accrued balance at September 30, 2016	$	76

From 2013 to 2015, Abbott management approved various plans to reduce costs and improve efficiencies across various functional areas. In the first nine months of 2016, charges of approximately $12 million were recognized as Selling, general and administrative expense. In 2013, Abbott management also approved plans to streamline certain manufacturing operations in order to reduce costs and improve efficiencies in Abbott’s established pharmaceuticals business. In 2012, Abbott management approved plans to streamline various commercial operations in order to reduce costs and improve efficiencies in Abbott’s core diagnostics, established pharmaceuticals and nutritionals businesses. The following summarizes the activity for the first nine months of 2016 related to these restructuring actions and the status of the related accrual as of September 30, 2016:

(in millions)
Accrued balance at December 31, 2015	$	88
Restructuring charges recorded in 2016	12
Payments and other adjustments	(65		)
Accrued balance at September 30, 2016	$	35

In 2013 and prior years, Abbott management approved plans to streamline global manufacturing operations, reduce overall costs and improve efficiencies in its worldwide pharmaceutical, vascular and core diagnostics businesses as well as selected domestic and international commercial and research and development operations. The following summarizes the activity for the first nine months of 2016 related to these restructuring actions and the status of the related accrual as of September 30, 2016:

(in millions)
Accrued balance at December 31, 2015	$	11
Payments and other adjustments	(6		)
Accrued balance at September 30, 2016	$	5

Table of Contents

Note 9 — Incentive Stock Programs

In the first nine months of 2016, Abbott granted 7,699,301 stock options, 776,510 restricted stock awards and 7,467,430 restricted stock units under its incentive stock programs. At September 30, 2016, approximately 57 million shares were reserved for future grants. Information regarding the number of stock options outstanding and exercisable at September 30, 2016 is as follows:

	Outstanding		Exercisable
Number of shares	36,376,374		23,861,634
Weighted average remaining life (years)	5.4		3.7
Weighted average exercise price	$	34.01	$	30.36
Aggregate intrinsic value (in millions)	$	328	$	294

The total unrecognized share-based compensation cost at September 30, 2016 amounted to approximately $237 million which is expected to be recognized over the next three years.

Note 10 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $2.9 billion at September 30, 2016 and $2.4 billion at December 31, 2015 are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September 30, 2016 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months. The amount of hedge ineffectiveness was not significant in 2016 and 2015.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies including the British pound, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At September 30, 2016 and December 31, 2015, Abbott held the gross notional amount of $15.5 billion and $14.0 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated foreign denominated short-term debt as a hedge of the net investment in a foreign subsidiary of approximately $522 million and approximately $439 million as of September 30, 2016 and December 31, 2015, respectively. Accordingly, changes in the reported value of this debt due to changes in exchange rates are recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts totaling approximately $4.0 billion at September 30, 2016 and December 31, 2015 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. The amount of hedge ineffectiveness was not significant in 2016 and 2015.

Table of Contents

The following table summarizes the amounts and location of certain derivative financial instruments as of September 30, 2016 and December 31, 2015:

	Fair Value - Assets					Fair Value - Liabilities
(in millions)	Sept. 30, 2016		Dec. 31, 2015		Balance Sheet Caption	Sept. 30, 2016		Dec. 31, 2015		Balance Sheet Caption
Interest rate swaps designated as fair value hedges	$	211	$	116	Deferred income taxes and other assets	$	—	$	—	n/a

Foreign currency forward exchange contracts:
Hedging instruments	28		64		Prepaid expenses and other receivables	97		18		Other accrued liabilities
Others not designated as hedges	122		115		Prepaid expenses and other receivables	59		84		Other accrued liabilities

Debt designated as a hedge of net investment in a foreign subsidiary	—		—		n/a	522		439		Short-term borrowings
	$	361	$	295		$	678	$	541

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months and nine months ended September 30, 2016 and 2015. The amount of hedge ineffectiveness was not significant in 2016 and 2015 for these hedges.

	Gain (loss) Recognized in Other Comprehensive Income (loss)											Income (expense) and Gain (loss) Reclassified into Income
	Three Months Ended Sept. 30						Nine Months Ended Sept. 30					Three Months Ended Sept. 30					Nine Months Ended Sept. 30				Income Statement
(in millions)	2016			2015			2016			2015		2016			2015		2016		2015		Caption

Foreign currency forward exchange contracts designated as cash flow hedges	$	(45	)	$	41		$	(96	)	$	89	$	5		$	33	$	59	$	80	Cost of products sold

Debt designated as a hedge of net investment in a foreign subsidiary	(6		)	(11		)	(83		)	3		n/a			n/a		n/a		n/a		n/a

Interest rate swaps designated as fair value hedges	n/a			n/a			n/a			n/a		(50		)	85		95		71		Interest expense

Losses of $5 million and $9 million were recognized in the three months ended September 30, 2016 and 2015, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Gains of $16 million and $92 million were recognized in the nine months ended September 30, 2016 and 2015, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange loss (gain) line.

The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The hedged debt is marked to market, offsetting the effect of marking the interest rate swaps to market.

Table of Contents

The carrying values and fair values of certain financial instruments as of September 30, 2016 and December 31, 2015 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from nonperformance by these counterparties.

	September 30, 2016						December 31, 2015
(in millions)	Carrying Value			Fair Value			Carrying Value			Fair Value
Investment Securities:
Equity securities	$	2,946		$	2,946		$	4,014		$	4,014
Other	51			55			27			30
Total Long-term Debt	(5,979		)	(6,665		)	(5,874		)	(6,337		)
Foreign Currency Forward Exchange Contracts:
Receivable position	150			150			179			179
(Payable) position	(156		)	(156		)	(102		)	(102		)
Interest Rate Hedge Contracts:
Receivable position	211			211			116			116

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

			Basis of Fair Value Measurement
(in millions)	Outstanding Balances		Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
September 30, 2016:
Equity securities	$	2,675	$	2,675	$	—	$	—
Interest rate swap derivative financial instruments	211		—		211		—
Foreign currency forward exchange contracts	150		—		150		—
Total Assets	$	3,036	$	2,675	$	361	$	—

Fair value of hedged long-term debt	$	4,238	$	—	$	4,238	$	—
Foreign currency forward exchange contracts	156		—		156		—
Contingent consideration related to business combinations	163		—		—		163
Total Liabilities	$	4,557	$	—	$	4,394	$	163

December 31, 2015:
Equity securities	$	3,780	$	3,780	$	—	$	—
Interest rate swap derivative financial instruments	116		—		116		—
Foreign currency forward exchange contracts	179		—		179		—
Total Assets	$	4,075	$	3,780	$	295	$	—

Fair value of hedged long-term debt	$	4,135	$	—	$	4,135	$	—
Foreign currency forward exchange contracts	102		—		102		—
Contingent consideration related to business combinations	173		—		—		173
Total Liabilities	$	4,410	$	—	$	4,237	$	173

Equity securities are principally comprised of Mylan N.V. ordinary shares. The fair value of the Mylan equity securities was determined based on the value of the publicly-traded ordinary shares. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis. The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of the contingent consideration was determined based on an independent appraisal adjusted for the time value of money and other changes in fair value primarily resulting from changes in regulatory timelines.

Table of Contents

Note 11 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $40 million to $45 million. The recorded accrual balance at September 30, 2016 for these proceedings and exposures was approximately $45 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

Note 12 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net cost recognized in continuing operations for the three months and nine months ended September 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:

	Defined Benefit Plans												Medical and Dental Plans
	Three Months						Nine Months						Three Months						Nine Months
	Ended Sept. 30						Ended Sept. 30						Ended Sept. 30						Ended Sept. 30
(in millions)	2016			2015			2016			2015			2016			2015			2016			2015
Service cost - benefits earned during the period	$	66		$	80		$	200		$	230		$	7		$	9		$	20		$	24
Interest cost on projected benefit obligations	72			78			218			234			11			14			33			39
Expected return on plan assets	(142		)	(128		)	(426		)	(385		)	(9		)	(10		)	(26		)	(29		)
Net amortization of:
Actuarial loss, net	34			47			97			136			4			8			13			18
Prior service cost (credit)	—			—			—			—			(12		)	(12		)	(34		)	(36		)
Total cost	30			77			89			215			1			9			6			16
Less: Discontinued operations	—			—			—			1			—			—			—			—
Net cost - continuing operations	$	30		$	77		$	89		$	214		$	1		$	9		$	6		$	16

Abbott funds its domestic defined benefit plans according to IRS funding limitations. International pension plans are funded according to similar regulations. In the first nine months of 2016 and 2015, $540 million and $551 million, respectively, were contributed to defined benefit plans and $9 million and $24 million, respectively, were contributed to the post-employment medical and dental benefit plans.

Table of Contents

Note 13 — Taxes on Earnings

Taxes on earnings from continuing operations reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2016, taxes on earnings from continuing operations includes the impact of a net tax benefit of approximately $250 million as a result of the resolution of various tax positions from prior years, partially offset by the unfavorable impact of non-deductible foreign exchange losses related to Venezuela and the adjustment of the Mylan N.V. equity investment as well as the recognition of deferred taxes associated with the pending sale of AMO. Earnings from discontinued operations, net of tax, in the first nine months of 2016 reflects the recognition of $289 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately $546 million. In the first nine months of 2015, taxes on earnings from continuing operations include a tax cost of $71 million related to the disposal of shares of Mylan N.V. stock. Taxes on earnings from continuing operations in the first nine months of 2015 were not affected by any adjustments as the result of the resolution of various tax positions pertaining to prior years. 2015 tax expense related to discontinued operations includes $667 million of tax expense on certain funds earned outside the U.S. in 2015 that were not designated as permanently reinvested overseas. Earnings from discontinued operations, net of tax, in the first nine months of 2015 also reflects the recognition of $10 million of net tax expense primarily as a result of the resolution of various tax positions related to AbbVie’s operations for years prior to the separation. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately $16 million.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease by $100 million to $200 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., Abbott’s federal income tax returns through 2013 are settled except for one issue.

Table of Contents

Note 14 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world. Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions are aggregated and reported as the Diagnostic Products segment.

Vascular Products — Worldwide sales of coronary, endovascular, structural heart, vessel closure and other medical device products. For segment reporting purposes, the Vascular and Electrophysiology Products divisions are aggregated and reported as the Vascular Products segment.

Non-reportable segments include the Diabetes Care and Medical Optics segments.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

	Net Sales to External Customers								Operating Earnings
	Three Months				Nine Months				Three Months						Nine Months
	Ended Sept. 30				Ended Sept. 30				Ended Sept. 30						Ended Sept. 30
(in millions)	2016		2015		2016		2015		2016			2015			2016			2015
Established Pharmaceutical Products	$	1,012	$	961	$	2,880	$	2,835	$	211		$	177		$	551		$	516
Nutritional Products	1,755		1,789		5,166		5,175		438			459			1,148			1,198
Diagnostic Products	1,213		1,156		3,557		3,426		301			307			856			887
Vascular Products	708		672		2,175		2,092		249			239			786			803
Total Reportable Segments	4,688		4,578		13,778		13,528		1,199			1,182			3,341			3,404
Other	614		572		1,742		1,689
Net Sales	$	5,302	$	5,150	$	15,520	$	15,217
Corporate functions and benefit plans costs									(107		)	(109		)	(282		)	(330		)
Non-reportable segments									105			76			155			193
Net interest expense (a)									(95		)	(16		)	(203		)	(49		)
Share-based compensation (b)									(49		)	(43		)	(263		)	(248		)
Amortization of intangible assets									(140		)	(151		)	(429		)	(458		)
Other, net (c)									(1,092		)	(225		)	(1,781		)	(159		)
Earnings (loss) from continuing operations before taxes									$	(179	)	$	714		$	538		$	2,353

(a) Net interest expense for the quarter and the nine months ended September 30, 2016 includes amortization expense associated with bridge facility fees.

(b) Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(c) Other, net for the nine months ended September 30, 2016, includes the $947 million adjustment of the Mylan equity investment and $481 million of foreign currency loss related to operations in Venezuela. Other, net for the nine months ended September 30, 2015, includes a gain on the sale of a portion of Abbott’s position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Financial Review - Results of Operations

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are nutritional products, branded generic pharmaceuticals, diagnostic testing products and vascular products.

The following table details sales by reportable segment for the three months and nine months ended September 30. Percent changes are versus the prior year and are based on unrounded numbers.

	Net Sales to External Customers
(in millions)	Three Months Ended Sept. 30, 2016		Three Months Ended Sept. 30, 2015		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange

Established Pharmaceutical Products	$	1,012	$	961	5.3	%	(3.7	)%	9.0	%
Nutritional Products	1,755		1,789		(2.0	)	(1.0	)	(1.0	)
Diagnostic Products	1,213		1,156		5.0		(0.4	)	5.4
Vascular Products	708		672		5.2		0.3		4.9
Total Reportable Segments	4,688		4,578		2.4		(1.2	)	3.6
Other	614		572		7.4		0.4		7.0
Net Sales	$	5,302	$	5,150	2.9		(1.1	)	4.0

Total U.S.	$	1,645	$	1,574	4.5		—		4.5

Total International	$	3,657	$	3,576	2.2		(1.5	)	3.7

	Net Sales to External Customers
(in millions)	Nine Months Ended Sept. 30, 2016		Nine Months Ended Sept. 30, 2015		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange

Established Pharmaceutical Products	$	2,880	$	2,835	1.6	%	(8.2	)%	9.8	%
Nutritional Products	5,166		5,175		(0.2	)	(2.7	)	2.5
Diagnostic Products	3,557		3,426		3.8		(2.3	)	6.1
Vascular Products	2,175		2,092		3.9		(1.0	)	4.9
Total Reportable Segments	13,778		13,528		1.8		(3.5	)	5.3
Other	1,742		1,689		3.2		(0.9	)	4.1
Net Sales	$	15,520	$	15,217	2.0		(3.2	)	5.2

Total U.S.	$	4,831	$	4,668	3.5		—		3.5

Total International	$	10,689	$	10,549	1.3		(4.6	)	5.9

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Net sales growth in the third quarter and first nine months of 2016 was negatively impacted by changes in foreign currency exchange rates. The relatively stronger U.S. dollar decreased total international sales by 1.5 percent and total sales by 1.1 percent in the third quarter. Excluding the unfavorable impact of foreign exchange, total net sales increased 4.0 percent in the third quarter of 2016, driven by higher revenues in the Established Pharmaceutical, Diagnostic and Vascular Products segments. Mid-single digit growth in emerging market sales contributed to the 3.7 percent increase in total international sales excluding the impact of foreign exchange for the third quarter of 2016.

Table of Contents

The table below provides detail by sales category for the nine months ended September 30. Percent changes are versus the prior year and are based on unrounded numbers.

(in millions)	Sept. 30, 2016		Sept. 30, 2015		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange
Established Pharmaceutical Products —
Key Emerging Markets	$	2,135	$	2,078	2.7	%	(10.7	)%	13.4	%
Other Emerging Markets	745		757		(1.5	)	(1.5	)	0.0

Nutritionals —
International Pediatric Nutritionals	1,664		1,753		(5.1	)	(4.4	)	(0.7	)
U.S. Pediatric Nutritionals	1,242		1,183		5.0		—		5.0
International Adult Nutritionals	1,278		1,279		(0.1	)	(4.8	)	4.7
U.S. Adult Nutritionals	982		960		2.3		—		2.3

Diagnostics —
Immunochemistry	2,721		2,605		4.5		(2.5	)	7.0

Vascular Products (1) —
Coronary Devices	1,636		1,626		0.6		(1.0	)	1.6
Endovascular	420		388		8.2		(1.2	)	9.4

(1) Coronary Devices include DES / BVS product portfolio, structural heart, guidewires, balloon catheters, and other coronary products. Endovascular includes vessel closure, carotid stents and other peripheral products.

Key Emerging Markets for the Established Pharmaceutical Products business include India, Russia, Brazil and China, along with several other markets that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets increased 13.4 percent compared to the first nine months of 2015 due to continued growth in India, Russia, China and several countries in Latin America. India comprises more than 20 percent of Established Pharmaceutical Product sales.

Excluding the effect of foreign exchange, the 0.7 percent decrease in International Pediatric Nutritional sales was primarily driven by challenging market conditions in China, partially offset by continued strong performance in several markets across Latin America and Southeast Asia. In the U.S., the 5.0 percent increase in Pediatric Nutritional sales reflects recent infant and toddler product launches including Similac® Advance® Non-GMO and Go & Grow® by Similac® Non-GMO. Excluding the effect of foreign exchange, the 4.7 percent increase in International Adult Nutritional sales reflects continued strong growth in several emerging markets. The 2.3 percent increase in U.S. Adult Nutritional sales was driven by the growth of Ensure® in the retail and institutional market segments.

Excluding the effect of foreign exchange, the 6.1 percent increase in total Diagnostics sales was primarily driven by share gains in the Core Laboratory and Point of Care markets in the U.S. and internationally, including double-digit growth for Core Laboratory in emerging markets. In the Vascular Products segment, double-digit growth in sales of Abbott’s MitraClip structural heart device for the treatment of mitral regurgitation was partially offset by lower sales of DES products. The increase in the Endovascular business was driven by higher Supera and vessel closure sales. Vascular Products sales were also favorably impacted by the resolution of previously disputed third party royalty revenue related to the prior year. Excluding this royalty impact, worldwide sales of Vascular Products would have increased 2.5 percent during the first nine months of 2016.

The gross profit margin percentage was 54.3 percent for the third quarter of 2016 compared to 53.5 percent for the third quarter of 2015. The gross profit margin percentage was 54.0 percent for the first nine months of 2016 and 2015. For the first nine months of 2016, the impact of gross margin improvement initiatives across the divisions was offset by the effect of unfavorable foreign exchange.

Research and development expenses decreased by $26 million, or 6.7 percent, in the third quarter of 2016 due primarily to lower restructuring costs in 2016 partially offset by higher spending on various projects. In the first nine months of 2016, research and development expenses increased by $43 million, or 4.2 percent, due primarily to higher spending on various projects and the impairment of an in-process research and development asset related to a non-reportable segment partially offset by lower restructuring costs in 2016. For the nine months ended September 30, 2016, research and development expenditures totaled $188 million for the Vascular Products segment, $383 million for the Diagnostic Products segment, $99 million for the Established Pharmaceutical Products segment and $159 million for the Nutritional Products segment.

Table of Contents

Selling, general and administrative expenses for the third quarter and first nine months of 2016 decreased 2.3 percent and 1.3 percent, respectively, as higher spending to support the growth of various products was more than offset by the impact of cost improvement initiatives and the favorable impact of foreign exchange.

On September 30, 2016, Abbott recorded expense of $947 million to adjust its holding of Mylan N.V. ordinary shares due to a decline in the fair value of the securities which is considered by Abbott to be other than temporary. The adjustment reflects Mylan’s share price as of September 30, 2016 and is included in the Other expense (income), net line of the Condensed Consolidated Statement of Earnings.

Business Acquisitions

On October 21, 2016, Alere shareholders approved the acquisition.

On October 26, 2016, St. Jude Medical shareholders approved the acquisition.

Table of Contents

Restructuring Plans

The results for the first nine months of 2016 reflect charges recognized for actions associated with the company’s plans to streamline various operations in order to reduce costs and improve efficiencies. Abbott recorded employee related severance and other charges of approximately $35 million in 2016 related to these initiatives. Approximately $7 million is recognized in Cost of products sold and approximately $28 million is recognized in Selling, general and administrative expense. See Note 8 to the financial statements, “Restructuring Plans,” for additional information regarding these charges.

Interest Expense (Income), net

Interest expense (income), net increased $79 million in the third quarter of 2016 and $154 million in the first nine months of 2016 compared to 2015 due to higher interest expense in 2016 associated with the amortization of bridge financing fees related to the financing of the two pending acquisitions. The increase in the first nine months of 2016 also reflects higher interest expense related to the long-term debt issued in March of 2015.

Taxes on Earnings from Continuing Operations

Separation of AbbVie Inc.

Abbott has retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation, as well as certain non-income taxes attributable to AbbVie’s business prior to the separation. AbbVie generally will be liable for all other taxes

Table of Contents

attributable to its business. Net earnings from discontinued operations reflect the recognition of $282 million of tax benefit and $10 million of tax expense in the first nine months of 2016 and 2015, respectively, as a result of the resolution of various tax positions related to AbbVie’s operations for years prior to the separation.

Discontinued Operations

As a result of the disposition of Abbott’s developed markets branded generics pharmaceuticals and animal health businesses, the current and prior years’ operating results of these businesses up to the date of sale are reported as part of discontinued operations on the Earnings from discontinued operations, net of tax line in the Condensed Consolidated Statement of Earnings. The cash flows associated with the developed markets branded generics pharmaceuticals and animal health businesses are included in Abbott’s Condensed Consolidated Statement of Cash Flows up to the date of disposition.

The operating results of Abbott’s developed markets branded generics pharmaceuticals, animal health and AbbVie businesses, which are being reported as discontinued operations are as follows:

	Three Months Ended Sept. 30						Nine Months Ended Sept. 30
(in millions)	2016			2015			2016			2015
Net Sales
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	—		$	—		$	256
AbbVie	—			—			—			—
Total	$	—		$	—		$	—		$	256
Earnings (Loss) Before Tax
Developed markets generics pharmaceuticals and animal health businesses	$	5		$	(6	)	$	(1	)	$	14
AbbVie	—			—			—			—
Total	$	5		$	(6	)	$	(1	)	$	14
Income Tax Expense (Benefit)
Developed markets generics pharmaceuticals and animal health businesses	$	(4	)	$	(1	)	$	(7	)	$	11
AbbVie	(19		)	27			(282		)	10
Total	$	(23	)	$	26		$	(289	)	$	21
Net Earnings (Loss)
Developed markets generics pharmaceuticals and animal health businesses	$	9		$	(5	)	$	6		$	3
AbbVie	19			(27		)	282			(10		)
Total	$	28		$	(32	)	$	288		$	(7	)

In the first nine months of 2016, Abbott received an additional $25 million of proceeds related to the expiration of a holdback agreement associated with the sale of the animal health business and reported an after-tax gain on the sale in discontinued operations of $16 million. The sale of the developed markets branded generics pharmaceuticals and animal health businesses in the first nine months of 2015 resulted in the recognition of a pretax gain of $2.837 billion, tax expense of $1.085 billion and an after-tax gain of $1.752 billion.

Assets and Liabilities Held for Disposition

Table of Contents

(in millions)	September 30, 2016		December 31, 2015
Trade receivables, net	$	226	$	17
Total inventories	247		43
Prepaid expenses and other current assets	79		45
Current assets held for disposition	552		105
Net property and equipment	238		1
Intangible assets, net of amortization	533		—
Goodwill	1,986		—
Deferred income taxes and other assets	22		1
Non-current assets held for disposition	2,779		2
Total assets held for disposition	$	3,331	$	107

Trade accounts payable	$	421	$	359
Salaries, wages, commissions and other accrued liabilities	176		14
Current liabilities held for disposition	597		373
Post-employment obligations, deferred income taxes and other long-term liabilities	60		—
Total liabilities held for disposition	$	657	$	373

Liquidity and Capital Resources September 30, 2016 Compared with December 31, 2015

The reduction of cash and cash equivalents from $5.0 billion at December 31, 2015 to $2.5 billion at September 30, 2016 reflects repayment of short-term debt, pension contributions, share repurchases and the Venezuela foreign currency loss, as well as dividends paid during the year and an increase in short-term investments.

Net cash from operating activities for the first nine months of 2016 totaled $2.0 billion. Other, net in Net cash from operating activities for the first nine months of 2016 includes contributions to defined benefit pension plans of $540 million as well as approximately $140 million of cash taxes paid related to the disposition of businesses. Other, net in 2016 also includes the non-cash impact of approximately $539 million of net tax benefits primarily associated with the resolution of various tax positions from prior years. In the first nine months of 2015, Other, net in Net cash from operating activities included the contributions to defined benefit pension plans of $551 million, as well as approximately $150 million related to cost reduction and business disposal activities. Other, net in 2015 also included the non-cash impact of $1.1 billion of tax expense associated with the gain on the sale of businesses. The foreign currency loss related to Venezuela in the first nine months of 2016 reduced Abbott’s cash by approximately $410 million and is shown on the Effect of exchange rate changes on cash and cash equivalents line within the Condensed Consolidated Statement of Cash Flows. Abbott expects to fund cash dividends, capital expenditures and its other investments in its businesses with cash flow from operating activities, cash on hand, short-term investments and borrowings.

Working capital was $4.7 billion at September 30, 2016 and $5.0 billion at December 31, 2015. The $0.3 billion decrease in working capital in 2016 is primarily due to the reduction in Cash and cash equivalents driven by pension contributions, share repurchases, the Venezuela foreign currency loss and dividends paid.

A majority of Abbott’s trade receivables in Italy, Spain, Portugal, and Greece are with governmental health systems. Governmental receivables in these four countries accounted for less than 1% of Abbott’s total assets and 8% of total net trade receivables as of September 30, 2016 as compared to less than 1% of total assets and 7% of total net trade receivables as of December 31, 2015. With the exception of Greece, Abbott historically has collected almost all of the outstanding receivables in these countries. Abbott closely monitors economic conditions and budgetary and other fiscal developments in these countries. Abbott regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. Abbott also monitors the potential for and periodically has utilized factoring arrangements to mitigate risk although such arrangements were not material in the first nine months of 2016.

Table of Contents

position, and cash flows related to its operations in Venezuela since Abbott continued to qualify for this exchange rate to pay for the import of various products into Venezuela.

At September 30, 2016, Abbott’s long-term debt rating was A+ by Standard & Poor’s Corporation and A2 by Moody’s Investors Service. As a result of Abbott’s announced agreements to acquire Alere and St. Jude Medical, Abbott’s credit ratings are under review and it is anticipated that the ratings will be adjusted to reflect the increased borrowings that will be incurred to finance these acquisitions. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources, including unused lines of credit of $5.0 billion that support commercial paper borrowing arrangements which expire in 2019.

In September 2014, the board of directors authorized the repurchase of up to $3.0 billion of Abbott’s common shares from time to time. The 2014 authorization was in addition to the $512 million unused portion of a previous program announced in June 2013. In the first nine months of 2016, Abbott repurchased 10.4 million shares at a cost of $408 million under the program authorized in 2014. In the first nine months of 2015, Abbott repurchased 11.3 million shares at a cost of $512 million under the unused portion of the 2013 authorization and 15.6 million shares at a cost of $738 million under the program authorized in 2014 for a total of 26.9 million shares at a cost of $1.25 billion.

On April 27, 2016, the board of directors authorized the issuance and sale for general corporate purposes of up to 75 million common shares that would result in proceeds of up to $3 billion.

In each of the first three quarters of 2016, Abbott declared a quarterly dividend of $0.26 per share on its common shares, which represents an 8% increase over the $0.24 per share quarterly dividend declared in each of the first three quarters of 2015.

Recently Issued Accounting Standards

In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-09, Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 modifies several aspects of the accounting for share-based payment transactions, including the accounting for income taxes and classification on the statement of cash flows. The standard becomes effective for Abbott beginning in the first quarter of 2017 and early adoption is permitted. Abbott does not anticipate that the new guidance will have a material impact on its consolidated financial statements. Abbott cannot predict the impact on its consolidated financial statements in future reporting periods following adoption as this will be dependent upon various factors including the number of shares issued and changes in the price of its shares.

In February 2016, the FASB issued ASU 2016-02, Leases, which requires lessees to recognize assets and liabilities for most leases on the balance sheet. The standard becomes effective for Abbott beginning in the first quarter of 2019 and early adoption is permitted. Adoption requires application of the new guidance for all periods presented. Abbott is currently evaluating the impact the new guidance will have on its consolidated financial statements.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments — Recognition and Measurement of Financial Assets and Financial Liabilities, which provides new guidance for the recognition, measurement, presentation, and disclosure of financial assets and liabilities. The standard becomes effective for Abbott beginning in the first quarter of 2018 and early adoption is permitted. Abbott is currently evaluating the effect, if any, that the standard will have on its consolidated financial statements and related disclosures.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for accounting for revenue from contracts with customers and will supersede most existing revenue recognition guidance. The standard becomes effective for Abbott in the first quarter of 2018. Abbott is currently evaluating the effect, if any, that the standard will have on its consolidated financial statements and related disclosures.

Table of Contents

Legislative Issues

Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the 2015 Annual Report on Form 10-K and in Item 1A, Risk Factors, in the quarterly report for the quarter ended June 30, 2016.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions investors that any forward-looking statements or projections made by Abbott, including those made in this document, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, Risk Factors, in the 2015 Annual Report on Form 10-K and in Item 1A, Risk Factors, in the quarterly report for the quarter ended June 30, 2016.

PART I. FINANCIAL INFORMATION

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Market Price Sensitive Investments

The fair value of the available-for-sale equity securities held by Abbott was approximately $2.7 billion as of September 30, 2016 and $3.8 billion as of December 31, 2015. The decrease is due primarily to a decrease in the share price of the ordinary shares of Mylan N.V. that Abbott received in the sale of its developed markets branded generics pharmaceuticals business and that it continued to hold at September 30, 2016. All available-for-sale equity securities are subject to potential changes in market value. A hypothetical 20 percent decrease in the share prices of these investments would decrease their fair value at September 30, 2016 by approximately $540 million. Abbott monitors these investments for other than temporary declines in market value, and records a loss in income when an other than temporary decline in value occurs.

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures. The Chief Executive Officer, Miles D. White, and Chief Financial Officer, Brian B. Yoor, evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(b) Changes in internal control over financial reporting. During the quarter ended September 30, 2016, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations, including (as of September 30, 2016, except where noted below) those described below. While it is not feasible to predict the outcome of such pending claims, proceedings and investigations with certainty, management is of the opinion that their ultimate resolution should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

In its Form 10-Q for the quarter ended June 30, 2016, Abbott reported that two purported shareholder derivative class action lawsuits had been filed against St. Jude Medical, its board of directors, and Abbott and two of its subsidiaries in the Minnesota District

Table of Contents

Court, Second Judicial District (Ramsey County), alleging that the St. Jude Medical board of directors had breached its fiduciary duties by entering into an acquisition agreement with Abbott, and that Abbott had aided and abetted those breaches. In August 2016, a third purported shareholder derivative class lawsuit was filed, and all three lawsuits are being consolidated. The plaintiffs seek injunctive relief, as well as actual and punitive damages. Abbott denies all substantive allegations in these cases.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Period	(a) Total Number of Shares (or Units) Purchased		(b) Average Price Paid per Share (or Unit)		(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
July 1, 2016 – July 31, 2016	34,827	(1)	$	44.278	—	$	925,131,209	(2)
August 1, 2016 – August 31, 2016	24,295	(1)	$	45.121	—	$	925,131,209	(2)
September 1, 2016 – September 30, 2016	18,000	(1)	$	40.815	—	$	925,131,209	(2)
Total	77,122	(1)	$	43.735	—	$	925,131,209	(2)

(1) These shares include:

(i) the shares deemed surrendered to Abbott to pay the exercise price in connection with the exercise of employee stock options – 34,827 in July, 6,295 in August, and 0 in September; and

(ii) the shares purchased on the open market for the benefit of participants in the Abbott Laboratories, Limited Employee Stock Purchase Plan – 0 in July, 18,000 in August, and 18,000 in September.

These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

(2) On September 11, 2014, Abbott announced that its board of directors approved the purchase of up to $3 billion of its common shares, from time to time.

Item 6. Exhibits

Incorporated by reference to the Exhibit Index included herewith.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ABBOTT LABORATORIES

By:	/s/ Brian B. Yoor
	Brian B. Yoor
	Senior Vice President, Finance
	and Chief Financial Officer

	Date: November 3, 2016

Table of Contents

EXHIBIT INDEX

Exhibit No.		Exhibit

2.1		Stock Purchase Agreement, dated as of September 14, 2016, by and between Abbott Laboratories and Chace LLC and, solely for certain purposes, Johnson & Johnson, filed as Exhibit 2.1 to the Abbott Laboratories Current Report on Form 8-K dated September 14, 2016.

12		Statement re: Computation of ratio of earnings to fixed charges.

31.1		Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

31.2		Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.

32.1		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter and nine months ended September 30, 2016, formatted in XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Cash Flows; and (v) Notes to the Condensed Consolidated Financial Statements.

EX-12 2 a16-17215_1ex12.htm EX-12

Exhibit 12

Abbott Laboratories and Subsidiaries

Computation of Ratio of Earnings to Fixed Charges

(Unaudited)

(dollars in millions)

	Nine Months Ended
	September 30, 2016
Earnings from Continuing Operations	$	298
Add (deduct):
Taxes on earnings	240
Capitalized interest cost, net of amortization	(2		)
Noncontrolling interests	13

Earnings from Continuing Operations, as adjusted	549

Fixed Charges:
Interest on long-term and short-term debt	278
Capitalized interest cost	16
Rental expense representative of an interest factor	74

Total Fixed Charges	368

Total adjusted earnings available for payment of fixed charges	$	917

Ratio of earnings to fixed charges	2.5

NOTE: For the purpose of calculating this ratio, (i) earnings from continuing operations have been calculated by adjusting earnings for taxes on earnings; interest expense; capitalized interest cost, net of amortization; noncontrolling interests; and the portion of rentals representative of the interest factor, (ii) Abbott considers one-third of rental expense to be the amount representing return on capital, and (iii) fixed charges comprise total interest expense, including capitalized interest and such portion of rentals.

EX-31.1 3 a16-17215_1ex31d1.htm EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer

Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))

I, Miles D. White, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;

4. Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and

5. Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s auditors and the audit committee of Abbott’s board of directors:

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.

Date: November 3, 2016	/s/ Miles D. White
	Miles D. White, Chairman of the Board and
	Chief Executive Officer

EX-31.2 4 a16-17215_1ex31d2.htm EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer

Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))

I, Brian B. Yoor, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.

Date: November 3, 2016	/s/ Brian B. Yoor
	Brian B. Yoor, Senior Vice President,
	Finance and Chief Financial Officer

EX-32.1 5 a16-17215_1ex32d1.htm EX-32.1

Exhibit 32.1

Certification Pursuant To

18 U.S.C. Section 1350

As Adopted Pursuant To

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended September 30, 2016 as filed with the Securities and Exchange Commission (the “Report”), I, Miles D. White, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Miles D. White
Miles D. White
Chairman of the Board and
Chief Executive Officer
November 3, 2016

A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 6 a16-17215_1ex32d2.htm EX-32.2

Exhibit 32.2

Certification Pursuant To

18 U.S.C. Section 1350

As Adopted Pursuant To

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended September 30, 2016 as filed with the Securities and Exchange Commission (the “Report”), I, Brian B. Yoor, Senior Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Brian B. Yoor
Brian B. Yoor
Senior Vice President, Finance
and Chief Financial Officer
November 3, 2016

EX-101.INS 7 abt-20160930.xml XBRL INSTANCE DOCUMENT 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2016-09-30 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-09-30 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2016-06-30 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-06-30 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-12-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2015-09-30 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-09-30 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2015-06-30 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-06-30 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-06-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-06-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2014-12-31 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-12-31 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-12-31 0000001800 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0000001800 us-gaap:EmployeeStockOptionMember 2016-09-30 0000001800 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0000001800 abt:RestrictedStockAwardsMember 2016-01-01 2016-09-30 0000001800 us-gaap:AllOtherSegmentsMember 2016-07-01 2016-09-30 0000001800 us-gaap:AllOtherSegmentsMember 2016-01-01 2016-09-30 0000001800 us-gaap:AllOtherSegmentsMember 2015-07-01 2015-09-30 0000001800 us-gaap:AllOtherSegmentsMember 2015-01-01 2015-09-30 0000001800 abt:AlereIncMember 2016-01-30 2016-01-30 0000001800 abt:StJudeMedicalInc.Member 2015-01-01 2015-12-31 0000001800 abt:RestructuringPlan2015And2014Member 2016-09-30 0000001800 abt:RestructuringPlan2015And2013Member 2016-09-30 0000001800 abt:RestructuringPlan2013AndPriorYearsMember 2016-09-30 0000001800 abt:RestructuringPlan2015And2014Member 2015-12-31 0000001800 abt:RestructuringPlan2015And2013Member 2015-12-31 0000001800 abt:RestructuringPlan2013AndPriorYearsMember 2015-12-31 0000001800 us-gaap:SellingGeneralAndAdministrativeExpensesMember abt:RestructuringPlan20162015And2014Member 2016-01-01 2016-09-30 0000001800 us-gaap:CostOfSalesMember abt:RestructuringPlan20162015And2014Member 2016-01-01 2016-09-30 0000001800 abt:TendyneHoldingsInc.Member 2015-08-01 2015-08-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-07-01 2016-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-07-01 2015-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2016-07-01 2016-09-30 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-07-01 2016-09-30 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-07-01 2016-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-09-30 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-09-30 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-01-01 2016-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2015-07-01 2015-09-30 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-07-01 2015-09-30 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-07-01 2015-09-30 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-01-01 2015-09-30 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-01-01 2015-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:VascularProductsMember 2016-07-01 2016-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2016-07-01 2016-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2016-07-01 2016-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2016-07-01 2016-09-30 0000001800 us-gaap:OperatingSegmentsMember 2016-07-01 2016-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:VascularProductsMember 2016-01-01 2016-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2016-01-01 2016-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2016-01-01 2016-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2016-01-01 2016-09-30 0000001800 us-gaap:OperatingSegmentsMember 2016-01-01 2016-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:VascularProductsMember 2015-07-01 2015-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2015-07-01 2015-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2015-07-01 2015-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2015-07-01 2015-09-30 0000001800 us-gaap:OperatingSegmentsMember 2015-07-01 2015-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:VascularProductsMember 2015-01-01 2015-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2015-01-01 2015-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2015-01-01 2015-09-30 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2015-01-01 2015-09-30 0000001800 us-gaap:OperatingSegmentsMember 2015-01-01 2015-09-30 0000001800 abt:MyLanNVMember 2015-09-30 0000001800 abt:MyLanNVMember 2015-04-30 0000001800 abt:OtherLegalProceedingsAndEnvironmentalExposuresMember us-gaap:MinimumMember 2016-09-30 0000001800 abt:OtherLegalProceedingsAndEnvironmentalExposuresMember us-gaap:MaximumMember 2016-09-30 0000001800 abt:OtherLegalProceedingsAndEnvironmentalExposuresMember 2016-09-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2016-09-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2016-09-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2016-09-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2016-09-30 0000001800 us-gaap:OtherInvestmentsMember 2016-09-30 0000001800 us-gaap:EquitySecuritiesMember 2016-09-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2015-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2015-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2015-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2015-12-31 0000001800 us-gaap:OtherInvestmentsMember 2015-12-31 0000001800 us-gaap:EquitySecuritiesMember 2015-12-31 0000001800 2016-09-30 2016-09-30 0000001800 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember abt:AbbottMedicalOpticsMember 2016-07-01 2016-09-30 0000001800 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember abt:AbbottMedicalOpticsMember 2016-01-01 2016-09-30 0000001800 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember abt:AbbottMedicalOpticsMember 2015-07-01 2015-09-30 0000001800 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember abt:AbbottMedicalOpticsMember 2015-01-01 2015-09-30 0000001800 abt:VascularProductsMember 2016-09-30 0000001800 abt:NutritionalProductsMember 2016-09-30 0000001800 abt:EstablishedPharmaceuticalProductsMember 2016-09-30 0000001800 abt:DiagnosticProductsMember 2016-09-30 0000001800 abt:MylanMember 2015-04-01 2015-06-30 0000001800 abt:DICOMMember 2016-03-31 0000001800 abt:DIPROMember 2016-02-17 0000001800 abt:DIPROMember 2016-02-16 0000001800 currency:VEF 2015-12-31 0000001800 abt:CENCOEXMember 2015-12-31 0000001800 us-gaap:WeightedAverageMember 2016-01-01 2016-09-30 0000001800 us-gaap:MinimumMember 2016-01-01 2016-09-30 0000001800 us-gaap:MaximumMember 2016-01-01 2016-09-30 0000001800 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember abt:AbbottMedicalOpticsMember 2016-09-30 0000001800 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember abt:AbbottMedicalOpticsMember us-gaap:ScenarioForecastMember 2017-03-31 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-02-27 0000001800 abt:ProprietaryPharmaceuticalProductsMember 2015-01-01 2015-09-30 0000001800 us-gaap:SubsidiariesMember abt:ProprietaryPharmaceuticalProductsMember 2015-01-01 2015-09-30 0000001800 abt:AnimalHealthBusinessMember 2016-01-01 2016-03-31 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-02-27 2015-02-27 0000001800 abt:AnimalHealthBusinessMember 2015-02-10 2015-02-10 0000001800 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-07-01 2016-09-30 0000001800 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-01-01 2016-09-30 0000001800 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-07-01 2015-09-30 0000001800 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-01-01 2015-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2016-07-01 2016-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2016-07-01 2016-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2016-07-01 2016-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2016-01-01 2016-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2016-01-01 2016-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2016-01-01 2016-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2015-07-01 2015-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2015-07-01 2015-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2015-07-01 2015-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2015-01-01 2015-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2015-01-01 2015-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2015-01-01 2015-09-30 0000001800 us-gaap:ShortTermDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-09-30 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2016-09-30 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-09-30 0000001800 us-gaap:ShortTermDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2015-12-31 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-09-30 0000001800 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0000001800 abt:PrepaidExpensesDeferredIncomeTaxesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2016-09-30 0000001800 abt:PrepaidExpensesDeferredIncomeTaxesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-09-30 0000001800 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-09-30 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-09-30 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000001800 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000001800 abt:PrepaidExpensesDeferredIncomeTaxesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2015-12-31 0000001800 abt:PrepaidExpensesDeferredIncomeTaxesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000001800 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2015-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2015-12-31 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2016-07-01 2016-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2016-07-01 2016-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2015-07-01 2015-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2015-07-01 2015-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentDiscontinuedOperationsMember 2015-01-01 2015-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2015-01-01 2015-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2015-01-01 2015-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2016-07-01 2016-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2016-07-01 2016-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2016-01-01 2016-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2016-01-01 2016-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2015-07-01 2015-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2015-07-01 2015-09-30 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2015-01-01 2015-09-30 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2015-01-01 2015-09-30 0000001800 us-gaap:MinimumMember 2016-09-30 0000001800 us-gaap:MaximumMember 2016-09-30 0000001800 us-gaap:BridgeLoanMember 2016-02-01 2016-02-29 0000001800 2015-09-30 0000001800 2014-12-31 0000001800 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0000001800 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000001800 abt:MylanMember abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-01-01 2015-09-30 0000001800 abt:AlereIncMember 2016-01-30 0000001800 abt:StJudeMedicalInc.Member 2016-04-27 0000001800 us-gaap:MaximumMember 2016-02-29 0000001800 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0000001800 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0000001800 us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0000001800 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000001800 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000001800 us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2016-09-30 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2015-12-31 0000001800 abt:StJudeMedicalInc.Member abt:TerumoCorporationMember us-gaap:SupplyCommitmentMember 2016-10-18 0000001800 abt:RestructuringPlan2015And2014Member 2016-01-01 2016-09-30 0000001800 abt:RestructuringPlan2015And2013Member 2016-01-01 2016-09-30 0000001800 abt:RestructuringPlan2013AndPriorYearsMember 2016-01-01 2016-09-30 0000001800 abt:RestructuringPlan20162015And2014Member 2016-01-01 2016-09-30 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember us-gaap:MinimumMember 2015-02-27 2015-02-27 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember us-gaap:MaximumMember 2015-02-27 2015-02-27 0000001800 country:VE 2016-09-30 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2015-01-01 2015-09-30 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-01-01 2015-09-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2016-07-01 2016-09-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2016-01-01 2016-09-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2015-07-01 2015-09-30 0000001800 us-gaap:MaterialReconcilingItemsMember 2015-01-01 2015-09-30 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-01-01 2016-09-30 0000001800 us-gaap:SubsidiariesMember 2016-07-01 2016-09-30 0000001800 abt:DevelopedMarketsGenericsPharmaceuticalsAndAnimalHealthBusinessMember 2016-07-01 2016-09-30 0000001800 2016-07-01 2016-09-30 0000001800 us-gaap:SubsidiariesMember 2016-01-01 2016-09-30 0000001800 abt:DevelopedMarketsGenericsPharmaceuticalsAndAnimalHealthBusinessMember 2016-01-01 2016-09-30 0000001800 us-gaap:SubsidiariesMember 2015-07-01 2015-09-30 0000001800 abt:DevelopedMarketsGenericsPharmaceuticalsAndAnimalHealthBusinessMember 2015-07-01 2015-09-30 0000001800 2015-07-01 2015-09-30 0000001800 us-gaap:SubsidiariesMember 2015-01-01 2015-09-30 0000001800 abt:DevelopedMarketsGenericsPharmaceuticalsAndAnimalHealthBusinessMember 2015-01-01 2015-09-30 0000001800 2015-01-01 2015-09-30 0000001800 abt:NonReportableSegmentMember 2016-01-01 2016-09-30 0000001800 us-gaap:SubsidiariesMember abt:ProprietaryPharmaceuticalProductsHeldForDisposalMember 2016-09-30 0000001800 2016-09-30 0000001800 2015-12-31 0000001800 us-gaap:CorporateNonSegmentMember 2016-07-01 2016-09-30 0000001800 us-gaap:CorporateNonSegmentMember 2016-01-01 2016-09-30 0000001800 us-gaap:CorporateNonSegmentMember 2015-07-01 2015-09-30 0000001800 us-gaap:CorporateNonSegmentMember 2015-01-01 2015-09-30 0000001800 abt:MylanMember abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-02-27 0000001800 abt:MylanMember 2015-04-01 2015-04-30 0000001800 abt:MylanMember abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-02-27 2015-02-27 0000001800 abt:MyLanNVMember abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-01-01 2015-09-30 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2016-01-01 2016-09-30 0000001800 country:VE 2016-01-01 2016-09-30 0000001800 abt:TendyneHoldingsInc.Member 2015-08-31 0000001800 abt:StJudeMedicalInc.Member 2016-04-27 2016-04-27 0000001800 2016-01-01 2016-09-30 0000001800 abt:SICADMember 2015-12-31 0000001800 abt:SIMADIMember 2015-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 0.50 <div> <div>   Note 3 — Assets and Liabilities Held for Disposition   In September 2016, Abbott announced that it will sell Abbott Medical Optics (AMO), its vision care business, to Johnson & Johnson for $4.325 billion in cash. The decision to sell AMO reflects Abbott’s proactive shaping of its portfolio in line with its strategic priorities. The transaction is expected to close in the first quarter of 2017 and is subject to customary closing conditions, including regulatory approvals. The operating results of AMO do not qualify for reporting as discontinued operations. For the three months ended September 30, 2016 and 2015, AMO’s earnings (loss) before taxes were $2 million and $(2) million, respectively. For the first nine months ended September 30, 2016 and 2015, AMO’s earnings (loss) before taxes were $(42) million and $54 million, respectively. As a result of the planned sale of AMO, the assets and liabilities of this business meet the criteria to qualify as being held for disposition at September 30, 2016.   The assets and liabilities held for disposition as of September 30, 2016 relate to the AMO and AbbVie businesses. The assets and liabilities held for disposition as of December 31, 2015 relate to the AbbVie business.   The following is a summary of the assets and liabilities held for disposition:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:70.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> September 30, 2016 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2015 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"> Trade receivables, net </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>226  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Total inventories </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>247  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"> Prepaid expenses and other current assets </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>45  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Current assets held for disposition </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>552  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>105  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"> Net property and equipment </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>238  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Intangible assets, net of amortization </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>533  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,986  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Deferred income taxes and other assets </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"> Non-current assets held for disposition </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,779  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Total assets held for disposition </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,331  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Trade accounts payable </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>421  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>359  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"> Salaries, wages, commissions and other accrued liabilities </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>176  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Current liabilities held for disposition </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>597  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>373  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"> Post-employment obligations, deferred income taxes and other long-term liabilities </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Total liabilities held for disposition </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>657  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>373  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>     <div /></div> </div> 0.8708 18000000 82 410000000 140000000 110000000 110000000 110000000 0.22 330000000 109000000 282000000 107000000 1000000 22000000 60000000 306000000 14000000 176000000 59000000 -7000000 3000000 -10000000 -32000000 -5000000 -27000000 288000000 6000000 282000000 28000000 9000000 19000000 1902000000 593000000 297000000 -357000000 10000000 4000000 P12M 539000000 193000000 76000000 155000000 105000000 19000000 108000000 159000000 225000000 1781000000 1092000000 25000000 0.22 0.001 P2Y P10Y P3Y P2Y 2000000 6000000 65000000 47000000 40250000 40250000 <div> <div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:70.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> September 30, 2016 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2015 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"> Trade receivables, net </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>226  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Total inventories </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>247  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"> Prepaid expenses and other current assets </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>45  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Current assets held for disposition </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>552  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>105  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"> Net property and equipment </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>238  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Intangible assets, net of amortization </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>533  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,986  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Deferred income taxes and other assets </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"> Non-current assets held for disposition </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,779  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Total assets held for disposition </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,331  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Trade accounts payable </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>421  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>359  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"> Salaries, wages, commissions and other accrued liabilities </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>176  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14  </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Current liabilities held for disposition </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>597  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>373  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;"> Post-employment obligations, deferred income taxes and other long-term liabilities </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60  </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;"> Total liabilities held for disposition </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>657  </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>373  </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:70.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div> 1120000000 71000000 40.74 false --12-31 Q3 2016 2016-09-30 10-Q 0000001800 1472309523 Yes Large Accelerated Filer ABBOTT LABORATORIES 14000000000 2400000000 4000000000 15500000000 2900000000 4000000000 <div> <div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 90.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:66.66%;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;padding:0pt;"> September 30, </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:66.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Long-term Investments </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> Equity securities </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.10%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,946  </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.10%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,014  </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51  </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27  </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.10%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,997  </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.10%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,041  </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

1081000000

1051000000

3418000000

3320000000

430000000

240000000

6653000000

6718000000

65000000

-78000000

64000000

-60000000

-1958000000

-1972000000

-4829000000

-4423000000

-6658000000

-6533000000

248000000

43000000

263000000

49000000

337000000

284000000

458000000

151000000

429000000

140000000

658000

717000

5445000

12103000

41247000000

39497000000

14155000000

12978000000

4075000000

3780000000

295000000

3036000000

2675000000

361000000

107000000

3331000000

105000000

552000000

3780000000

2675000000

9000000000

17200000000

46.75

79000000

150000000

70000000

173000000

163000000

85000000

220000000

2500000000

5400000000

5800000000

24000000000

4063000000

3132000000

5001000000

2500000000

-931000000

-2501000000

0.72

0.24

0.78

0.26

2400000000

1702017390

1706957661

12734000000

12939000000

1371000000

-1627000000

727000000

361000000

6541000000

2242000000

6712000000

2285000000

13165000000

4437000000

13283000000

4405000000

P364D

200000000

100000000

-18000000

-136000000

-8000000

-47000000

-13000000

-97000000

-4000000

-34000000

-36000000

-12000000

-34000000

-12000000

24000000

551000000

9000000

540000000

29000000

385000000

10000000

128000000

26000000

426000000

9000000

142000000

39000000

234000000

14000000

78000000

33000000

218000000

11000000

72000000

16000000

215000000

16000000

214000000

1000000

9000000

77000000

9000000

77000000

6000000

89000000

6000000

89000000

1000000

30000000

1000000

30000000

24000000

230000000

9000000

80000000

20000000

200000000

7000000

66000000

648000000

605000000

295000000

179000000

64000000

115000000

179000000

116000000

361000000

150000000

28000000

122000000

150000000

211000000

541000000

102000000

18000000

84000000

102000000

439000000

678000000

156000000

97000000

59000000

156000000

522000000

<div> <div>   Note 10 — Financial Instruments, Derivatives and Fair Value Measures   Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar.  These contracts, with gross notional amounts totaling $2.9 billion at September 30, 2016 and $2.4 billion at December 31, 2015 are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value.  Accumulated gains and losses as of September 30, 2016 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.  The amount of hedge ineffectiveness was not significant in 2016 and 2015.   Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity.  For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies including the British pound, in exchange for primarily U.S. dollars and other European currencies.  For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies.  At September 30, 2016 and December 31, 2015, Abbott held the gross notional amount of $15.5 billion and $14.0 billion, respectively, of such foreign currency forward exchange contracts.   Abbott has designated foreign denominated short-term debt as a hedge of the net investment in a foreign subsidiary of approximately $522 million and approximately $439 million as of September 30, 2016 and December 31, 2015, respectively.  Accordingly, changes in the reported value of this debt due to changes in exchange rates are recorded in Accumulated other comprehensive income (loss), net of tax.   Abbott is a party to interest rate hedge contracts totaling approximately $4.0 billion at September 30, 2016 and December 31, 2015 to manage its exposure to changes in the fair value of fixed-rate debt.   These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates.  The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt.  Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.  The amount of hedge ineffectiveness was not significant in 2016 and 2015.   The following table summarizes the amounts and location of certain derivative financial instruments as of September 30, 2016 and December 31, 2015:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:37.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value - Assets </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:35.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value - Liabilities </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:23.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Sept. 30, 2016 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Dec. 31, 2015 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:20.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance Sheet Caption </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Sept. 30, 2016 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Dec. 31, 2015 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance Sheet Caption </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;"> Interest rate swaps designated as fair value hedges </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>211  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>116  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.00%;background-color: #CCEEFF;padding:0pt;"> Deferred income taxes and other assets </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.38%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.38%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:20.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;"> Foreign currency forward exchange contracts: </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;"> Hedging instruments </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>64  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:20.00%;padding:0pt;"> Prepaid expenses and other receivables </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>97  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;"> Other accrued liabilities </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;"> Others not designated as hedges </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>122  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>115  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.00%;background-color: #CCEEFF;padding:0pt;"> Prepaid expenses and other receivables </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>84  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> Other accrued liabilities </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:20.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;"> Debt designated as a hedge of net investment in a foreign subsidiary </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>522  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>439  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> Short-term borrowings </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.38%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>361  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.38%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>295  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:20.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.38%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>678  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.38%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>541  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:23.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:20.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months and nine months ended September 30, 2016 and 2015.  The amount of hedge ineffectiveness was not significant in 2016 and 2015 for these hedges.   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:21.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Gain (loss) Recognized in Other Comprehensive Income (loss) </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Income (expense) and Gain (loss) Reclassified into Income </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:21.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:13.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Three Months Ended Sept. 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:13.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Nine Months Ended Sept. 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:13.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Three Months Ended Sept. 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:13.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Nine Months Ended Sept. 30 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;"> Income Statement </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:21.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Caption </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:21.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:21.50%;background-color: #CCEEFF;padding:0pt;"> Foreign currency forward exchange contracts designated as cash flow hedges </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(45 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(96 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:04.86%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;padding:0pt;"> Cost of products sold </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:21.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:21.50%;background-color: #CCEEFF;padding:0pt;"> Debt designated as a hedge of net investment in a foreign subsidiary </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(83 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:21.50%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:21.50%;background-color: #CCEEFF;padding:0pt;"> Interest rate swaps designated as fair value hedges </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(50 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71 </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;padding:0pt;"> Interest expense </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   Losses of $5 million and $9 million were recognized in the three months ended September 30, 2016 and 2015, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Gains of $16 million and $92 million were recognized in the nine months ended September 30, 2016 and 2015, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange loss (gain) line.   The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates.  The hedged debt is marked to market, offsetting the effect of marking the interest rate swaps to market.   The carrying values and fair values of certain financial instruments as of September 30, 2016 and December 31, 2015 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values.  The counterparties to financial instruments consist of select major international financial institutions.  Abbott does not expect any losses from nonperformance by these counterparties.   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:50.10%;padding:0pt;">   </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> September 30, 2016 </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2015 </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:50.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Carrying Value </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Carrying Value </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:50.10%;background-color: #CCEEFF;padding:0pt;"> Investment Securities: </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:50.10%;padding:0pt;"> Equity securities </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,946 </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.06%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,946 </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.04%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,014 </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.06%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,014 </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:50.10%;background-color: #CCEEFF;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.36%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.36%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30 </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:50.10%;padding:0pt;"> Total Long-term Debt </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,979 </td> <td valign="bottom" style="width:02.88%;"> ) </td> <td colspan="2" valign="bottom" style="width:09.36%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,665 </td> <td valign="bottom" style="width:02.88%;"> ) </td> <td colspan="2" valign="bottom" style="width:09.34%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,874 </td> <td valign="bottom" style="width:02.88%;"> ) </td> <td colspan="2" valign="bottom" style="width:09.36%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,337 </td> <td valign="bottom" style="width:00.98%;"> ) </td> </tr> <tr> <td valign="top" style="width:50.10%;background-color: #CCEEFF;padding:0pt;"> Foreign Currency Forward Exchange Contracts: </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:50.10%;padding:0pt;"> Receivable position </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150 </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.36%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150 </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>179 </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.36%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>179 </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:50.10%;background-color: #CCEEFF;padding:0pt;"> (Payable) position </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(156 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:09.36%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(156 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:09.34%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(102 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:09.36%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(102 </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:50.10%;padding:0pt;"> Interest Rate Hedge Contracts: </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;padding:0pt;">   </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;padding:0pt;">   </td> <td valign="bottom" style="width:02.88%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.36%;padding:0pt;">   </td> <td valign="bottom" style="width:00.98%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:50.10%;background-color: #CCEEFF;padding:0pt;"> Receivable position </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>211 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.36%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>211 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.34%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>116 </td> <td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.36%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>116 </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The fair value of the debt was determined based on significant other observable inputs, including current interest rates.   The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the   balance sheet:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 93.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:37.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Basis of Fair Value Measurement </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding Balances </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Quoted Prices in Active Markets </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Other Observable Inputs </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Unobservable Inputs </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> September 30, 2016: </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Equity securities </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,675  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,675  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Interest rate swap derivative financial instruments </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>211  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>211  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>150  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Total Assets </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,036  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,675  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>361  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Fair value of hedged long-term debt </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,238  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,238  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>156  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>156  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Contingent consideration related to business combinations </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>163  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>163  </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Total Liabilities </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,557  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,394  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>163  </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> December 31, 2015: </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Equity securities </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,780  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,780  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Interest rate swap derivative financial instruments </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>116  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>116  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>179  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>179  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Total Assets </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,075  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,780  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>295  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Fair value of hedged long-term debt </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,135  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,135  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>102  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>102  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Contingent consideration related to business combinations </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173  </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Total Liabilities </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,410  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,237  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.50%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173  </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   Equity securities are principally comprised of Mylan N.V. ordinary shares.  The fair value of the Mylan equity securities was determined based on the value of the publicly-traded ordinary shares. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis. The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments.  The fair value of the contingent consideration was determined based on an independent appraisal adjusted for the time value of money and other changes in fair value primarily resulting from changes in regulatory timelines.   <div /></div> </div>

92000000

80000000

71000000

-9000000

33000000

85000000

16000000

59000000

95000000

-5000000

5000000

-50000000

3000000

89000000

-11000000

41000000

-83000000

-96000000

-6000000

-45000000

2837000000

25000000

1752000000

130000000

1600000000

16000000

14000000

-6000000

-1000000

5000000

-7000000

-32000000

288000000

28000000

21000000

11000000

10000000

26000000

-1000000

27000000

-289000000

-7000000

-282000000

-23000000

-4000000

-19000000

1100000000

1085000000

667000000

17000000

226000000

359000000

421000000

2000000

2779000000

5770000000

4325000000

1986000000

2000000000

533000000

43000000

247000000

2000000

2779000000

45000000

79000000

1000000

238000000

256000000

383000000

384000000

2.43

0.39

0.41

-0.22

2.41

0.38

0.40

-0.22

-170000000

-379000000

746000000

799000000

237000000

P3Y

5700000000

6100000000

560000000

410000000

420000000

450000000

490000000

10800000000

10500000000

P20Y

P2Y

P13Y

6.3

263

63000000

14000000

-497000000

-9000000

481000000

207000000

142000000

9638000000

7812000000

451000000

3000000000

286000000

3100000000

126000000

2353000000

54000000

714000000

-2000000

538000000

-42000000

-179000000

2000000

1911000000

596000000

298000000

-357000000

1.27

0.40

0.20

-0.24

1.26

0.39

0.20

-0.24

1745000000

-16000000

304000000

28000000

1.16

-0.01

0.21

0.02

1.15

-0.01

0.20

0.02

-947000000

442000000

118000000

240000000

178000000

151000000

116000000

213000000

152000000

-535000000

1001000000

10230000

9702000

6329000

419000000

325000000

72000000

5562000000

4674000000

122000000

41000000

278000000

117000000

-49000000

-16000000

-203000000

-95000000

116000000

211000000

116000000

211000000

1744000000

1763000000

2599000000

2613000000

539000000

524000000

316000000

326000000

73000000

25000000

75000000

22000000

41247000000

39497000000

9186000000

8321000000

4410000000

4237000000

173000000

4557000000

4394000000

163000000

373000000

657000000

373000000

597000000

60000000

3000000

4000000

5874000000

6337000000

4135000000

5979000000

6665000000

4238000000

5871000000

5975000000

4041000000

4014000000

27000000

4014000000

27000000

4014000000

30000000

2997000000

2946000000

51000000

2946000000

51000000

2946000000

55000000

45000000

40000000

P18M

115000000

120000000

0.14

-1739000000

-2357000000

-1160000000

-1798000000

2138000000

2033000000

3656000000

580000000

602000000

-329000000

3638000000

577000000

600000000

-329000000

2052000000

3404000000

887000000

516000000

1198000000

803000000

713000000

1182000000

307000000

177000000

459000000

239000000

2237000000

3341000000

856000000

551000000

1148000000

786000000

897000000

1199000000

301000000

211000000

438000000

249000000

3043000000

2715000000

1908000000

1986000000

2119000000

2523000000

-901000000

-1596000000

-143000000

613000000

89000000

-763000000

-1472000000

41000000

-1596000000

-645000000

-62000000

-77000000

-1118000000

406000000

-30000000

-362000000

89000000

9000000

8000000

-124000000

-27000000

2000000

-31000000

-7000000

-1472000000

-645000000

406000000

89000000

-2285000000

79000000

9000000

-901000000

-1472000000

-2207000000

26000000

8000000

-1596000000

-645000000

125000000

-14000000

-124000000

-143000000

406000000

690000000

15000000

-27000000

613000000

89000000

-79000000

-26000000

14000000

-15000000

39000000

14000000

5000000

8000000

104000000

-240000000

-28000000

4864000000

4245000000

287000000

3000000

-999000000

-972000000

170000000

2626000000

982000000

-43000000

-34000000

1349000000

522000000

1083000000

1153000000

225000000

235000000

73000000

862000000

802000000

1000000

230000000

25000000

2290000000

2485000000

-2019000000

-682000000

263000000

206000000

12383000000

12452000000

5730000000

5734000000

-79000000

80000000

138000000

-26000000

33000000

-48000000

47000000

-975000000

-15000000

-3000000

-975000000

36000000

11000000

1036000000

378000000

1079000000

352000000

12000000

23000000

7000000

16000000

11000000

88000000

100000000

5000000

35000000

76000000

25757000000

25162000000

5500000000

2500000000

15217000000

1689000000

13528000000

3426000000

2835000000

5175000000

2092000000

5150000000

572000000

4578000000

1156000000

961000000

1789000000

672000000

15520000000

1742000000

13778000000

3557000000

2880000000

5166000000

2175000000

5302000000

614000000

4688000000

1213000000

1012000000

1755000000

708000000

5130000000

1666000000

5063000000

1628000000

249000000

263000000

776510

7467430

57000000

294000000

23861634

30.36

P3Y8M12D

7699301

328000000

36376374

34.01

P5Y4M24D

3127000000

2531000000

1124000000

2007000000

21211000000

20776000000

-2229000000

99000000

1000000

-2924000000

-2157000000

100000000

696000000

-3643000000

-2131000000

108000000

-900000000

-4288000000

21326000000

-1958000000

64000000

65000000

-4829000000

-1987000000

-33000000

-691000000

-4512000000

20896000000

-1972000000

-60000000

-78000000

-4423000000

250000000

229352338

234648138

10622000000

10792000000

-16000000

-546000000

1509144000

1505167000

1482680000

1476366000

1498914000

1495465000

1476351000

1476366000

13.5

200

EX-101.SCH 8 abt-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00100 - Statement - Condensed Consolidated Statement of Earnings link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statement of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Balance Sheet link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Discontinued Operations - Assets And Liabilities Held For Disposition (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 41004 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Assets And Liabilities At Fair Value On A Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Post-Employment Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - Condensed Consolidated Statement of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - Condensed Consolidated Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Assets and Liabilities Held for Disposition link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Supplemental Financial Information link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Business Acquisitions link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Restructuring Plans link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Incentive Stock Programs link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Litigation and Environmental Matters link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Post-Employment Benefits link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Taxes on Earnings link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Assets and Liabilities Held for Disposition (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Supplemental Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Restructuring Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Incentive Stock Programs (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Post-Employment Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Discontinued Operations - (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Discontinued Operations - AbbVie Separation (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Assets and Liabilities Held for Disposition (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Supplemental Financial Information (Details). link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Business Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Business Acquisitions - St Jude Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Goodwill and Intangible Assets (Details). link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Restructuring Plans (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Incentive Stock Programs (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Derivative Information (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Derivative Instruments, Gain (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Values And Fair Values Of Certain Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Litigation and Environmental Matters (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Taxes on Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 abt-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 10 abt-20160930_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Document and Entity Information Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Condensed Consolidated Statement of Earnings Revenue, Net Net Sales Net Sales to External Customers Cost of Goods Sold Cost of products sold, excluding amortization of intangible assets Amortization of Intangible Assets Amortization of intangible assets Amortization of intangible assets Research and Development Expense (Excluding Acquired in Process Cost) Research and development Selling, General and Administrative Expense. Selling, general and administrative Costs and Expenses Total operating cost and expenses Operating Income (Loss) Operating Earnings Operating earnings Interest Expense. Interest expense Investment Income, Interest Interest (income) Foreign Currency Transaction Gain (Loss), before Tax Net foreign exchange loss (gain) Other Nonoperating Income (Expense) Other expense (income), net Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Earnings (loss) from continuing operations before taxes Earnings (loss) before taxes Income Tax Expense (Benefit) Taxes on earnings (loss) from continuing operations Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest Earnings (loss) from continuing operations Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Earnings (loss) from discontinued operations, net of tax Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Gain (loss) on sale of discontinued operations, net of tax After Tax Gain Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net earnings (loss) from discontinued operations, net of tax Net Income (Loss) Attributable to Parent Net Earnings (loss) Net earnings (loss) Net earnings Earnings Per Share, Basic [Abstract] Basic Earnings (Loss) Per Common Share - Income (Loss) from Continuing Operations, Per Basic Share Continuing operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Discontinued operations (in dollars per share) Earnings Per Share, Basic Net earnings (loss) (in dollars per share) Earnings Per Share, Diluted [Abstract] Diluted Earnings (Loss) Per Common Share - Income (Loss) from Continuing Operations, Per Diluted Share Continuing operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Discontinued operations (in dollars per share) Earnings Per Share, Diluted Net earnings (loss) (in dollars per share) Common Stock, Dividends, Per Share, Declared Cash Dividends Declared Per Common Share Weighted Average Number of Shares Outstanding, Basic Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Dilutive Common Stock Options (in shares) Weighted Average Number of Shares Outstanding, Diluted Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Outstanding Common Stock Options Having No Dilutive Effect (in shares) Condensed Consolidated Statement of Comprehensive Income Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation (loss) gain adjustments Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $8 and $5 in 2016 and $14 and $39 in 2015 Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Unrealized gains (losses) on marketable equity securities, net of taxes of $(28) and $(28) in 2016 and $(240) and $104 in 2015 Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $(7) and $(31) in 2016 and $2 and $2 in 2015 Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax: Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Cumulative foreign currency translation (loss) adjustments Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax Net actuarial (losses) and prior service cost and credits Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Cumulative unrealized (losses) gains on marketable equity securities Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax Cumulative (losses) gains on derivative instruments designated as cash flow hedges and other Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Tax Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, taxes Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax Unrealized (losses) gains on marketable equity securities, taxes Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Net gains (losses) for derivative instruments designated as cash flow hedges and other, taxes Condensed Consolidated Balance Sheet Assets [Abstract] Assets Assets, Current [Abstract] Current Assets: Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents, End of Period Cash and Cash Equivalents, Beginning of Year Cash and cash equivalents Short-term Investments Short-term investments Accounts Receivable, Net, Current Trade receivables, less allowances of $284 in 2016 and $337 in 2015 Inventory, Net [Abstract] Inventories: Inventory, Finished Goods, Gross Finished products Inventory, Work in Process, Gross Work in process Inventory, Raw Materials, Gross Materials Inventory, Net Total inventories Other Assets, Current Prepaid expenses and other receivables Assets of Disposal Group, Including Discontinued Operation, Current Current assets held for disposition Current assets held for disposition Assets, Current Total Current Assets Long-term Investments Investments Securities Investments Property, Plant and Equipment, Gross [Abstract] Property and Equipment, at Cost: Property, Plant and Equipment, Gross Property and equipment, at cost Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization Property, Plant and Equipment, Net Net property and equipment Intangible Assets, Net (Excluding Goodwill) Intangible assets, net of amortization Goodwill Goodwill Goodwill, non-deductible Other Assets, Noncurrent Deferred income taxes and other assets Disposal Group, Including Discontinued Operation, Other Noncurrent Assets Non-current assets held for disposition Assets Total Assets Liabilities and Equity [Abstract] Liabilities and Shareholders' Investment Liabilities, Current [Abstract] Current Liabilities: Short-term Debt Short-term borrowings Accounts Payable, Trade, Current Trade accounts payable Employee-related Liabilities, Current Salaries, wages and commissions Other Accrued Liabilities, Current Other accrued liabilities Dividends Payable, Current Dividends payable Accrued Income Taxes, Current Income taxes payable Long-term Debt, Current Maturities Current portion of long-term debt Liabilities of Disposal Group, Including Discontinued Operation, Current Current liabilities held for disposition Current liabilities held for disposition Liabilities, Current Total Current Liabilities Long-term Debt, Excluding Current Maturities Long-term debt Other Liabilities, Noncurrent Post-employment obligations, deferred income taxes and other long - term Liabilities Liabilities of Disposal Group, Including Discontinued Operation, Noncurrent Non-current liabilities held for disposition Commitments and Contingencies Commitments and Contingencies Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Shareholders' Investment: Preferred Stock, Value, Issued Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued Common Stock, Value, Issued Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2016: 1,706,957,661; 2015: 1,702,017,390 Treasury Stock, Value Common shares held in treasury, at cost - Shares: 2016: 234,648,138; 2015: 229,352,338 Retained Earnings (Accumulated Deficit) Earnings employed in the business Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income (loss) Stockholders' Equity Attributable to Parent Total Abbott Shareholders' Investment Stockholders' Equity Attributable to Noncontrolling Interest Noncontrolling Interests in Subsidiaries Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest End of Year Beginning of Year Total Shareholders' Investment Liabilities and Equity Total Liabilities and Shareholders' Investment Allowance for Doubtful Accounts Receivable, Current Trade receivables, allowances (in dollars) Preferred Stock, Par or Stated Value Per Share Preferred shares, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred shares, Authorized shares Preferred Stock, Shares Issued Preferred shares, issued shares Common Stock, Shares Authorized Common shares, Authorized shares Common Stock, Shares, Issued Common shares, Issued shares Treasury Stock, Shares Common shares held in treasury, shares Condensed Consolidated Statement of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flow From (Used in) Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net earnings to net cash from operating activities - Depreciation Depreciation Share-based Compensation Share-based compensation Foreign Currency Transaction Loss, before Tax Foreign Currency Transaction Loss, before Tax Foreign currency loss on remeasurement Impact of currency devaluation Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Gain on sale of discontinued operations Pretax Gain Income (Loss) from Equity Method Investments, Net of Dividends or Distributions Mylan N.V. equity investment adjustment Gain (Loss) on Sale of Equity Investments Gain on sale of Mylan N.V. shares Gain on sale of Mylan shares Gain on sale of Mylan N.V. shares Increase (Decrease) in Accounts Receivable Trade receivables Increase (Decrease) in Inventories Inventories Increase (Decrease) in Other Operating Assets and Liabilities, Net Other, net Net Cash Provided by (Used in) Operating Activities Net Cash From Operating Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flow From (Used in) Investing Activities: Payments to Acquire Property, Plant, and Equipment Acquisitions of property and equipment Proceeds from Divestiture of Businesses Proceeds from the disposition of business Proceeds from business disposition Payments to Acquire Businesses, Net of Cash Acquired Acquisitions of businesses and technologies, net of cash acquired Proceeds from Divestiture of Businesses and Interests in Affiliates Proceeds from the sale of Mylan N.V. shares Payments for (Proceeds from) Investments Sales (Purchases) of other investment securities, net Payments for (Proceeds from) Other Investing Activities Other Net Cash Provided by (Used in) Investing Activities Net Cash (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flow From (Used in) Financing Activities: Proceeds from (Repayments of) Short-term Debt Net (repayments of) proceeds from issuance of short-term debt and other Proceeds from Issuance of Long-term Debt Proceeds from the issuance of long-term debt Repayments of Long-term Debt Repayments of long-term debt Payment of Financing and Stock Issuance Costs Payment of debt issuance costs Represents the amount of cash paid for the contingent consideration. Payment of Contingent Consideration Payment of contingent consideration Payments for Repurchase of Common Stock Purchases of common shares Proceeds from Stock Options Exercised Proceeds from stock options exercised, including income tax benefit Payments of Dividends Dividends paid Net Cash Provided by (Used in) Financing Activities Net Cash (Used in) Financing Activities Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes on cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net Decrease in Cash and Cash Equivalents Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Basis of Presentation Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations No definition available. Assets and Liabilities Held for Disposition. The entire disclosure for assets and liabilities held for disposition. Assets and Liabilities Held for Disposition Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Supplemental Financial Information Changes in Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Changes in Accumulated Other Comprehensive Income (Loss) Business Acquisitions Business Combination Disclosure [Text Block] Business Acquisitions Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Restructuring Plans Restructuring and Related Activities Disclosure [Text Block] Restructuring Plans Incentive Stock Programs Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Incentive Stock Programs Financial Instruments, Derivatives and Fair Value Measures Derivative Instruments and Hedging Activities Disclosure [Text Block] Financial Instruments, Derivatives and Fair Value Measures Litigation and Environmental Matters Commitments and Contingencies Disclosure [Text Block] Litigation and Environmental Matters Post-Employment Benefits Postemployment Benefits Disclosure [Text Block] Post-Employment Benefits Taxes on Earnings Income Tax Disclosure [Text Block] Taxes on Earnings Segment Information Segment Reporting Disclosure [Text Block] Segment Information Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] Components of discontinued operations Tabular disclosure of disposal groups, which may include the classification and carrying value of the assets and liabilities comprising of the disposal group. Schedule of Disposal Groups Including Discontinued Operations Balance Sheet [Table Text Block] Summary of the assets and liabilities held for disposition Schedule of Debt [Table Text Block] Components of long-term investments Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Type Of Restructuring [Domain] Type of Restructuring [Domain] The entity's 2015 and 2014 restructuring plan to streamline global manufacturing and commercial operations in order to reduce costs and improve efficiencies in entity's core diagnostics, established pharmaceutical and nutritionals businesses. Restructuring Plan2015 And2014 [Member] Restructuring Plan 2016, 2015 and 2014 The entity's 2015 and 2013 restructuring plan to streamline global manufacturing and commercial operations in order to reduce costs and improve efficiencies in entity's core diagnostics, established pharmaceutical and nutritionals businesses. Restructuring Plan2015 And2013 [Member] Restructuring Plan 2013 to 2015 The entity's 2013 and prior years restructuring plans to realign its worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and research and development operations in order to reduce costs. Restructuring Plan2013 And Prior Years [Member] Restructuring Plan 2013 and Prior Years Restructuring and Related Cost [Abstract] Restructuring costs Restructuring and Related Costs [Table Text Block] Schedule of restructuring activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Stock options outstanding and exercisable Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Summary of the amounts and location of certain derivative financial instruments Derivative Instruments, Gain (Loss) [Table Text Block] Schedule of derivatives gain (loss) in OCI and earnings Fair Value, by Balance Sheet Grouping [Table Text Block] Schedule of carrying values and fair values of certain financial instruments EX-101.PRE 11 abt-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 12 abt-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2016 shares
Document and Entity Information
Entity Registrant Name	ABBOTT LABORATORIES
Entity Central Index Key	0000001800
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	1,472,309,523
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Earnings - USD ($) shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Condensed Consolidated Statement of Earnings
Net Sales	$ 5,302	$ 5,150	$ 15,520	$ 15,217
Cost of products sold, excluding amortization of intangible assets	2,285	2,242	6,712	6,541
Amortization of intangible assets	140	151	429	458
Research and development	352	378	1,079	1,036
Selling, general and administrative	1,628	1,666	5,063	5,130
Total operating cost and expenses	4,405	4,437	13,283	13,165
Operating earnings	897	713	2,237	2,052
Interest expense	117	41	278	122
Interest (income)	(22)	(25)	(75)	(73)
Net foreign exchange loss (gain)	9	(14)	497	(63)
Other expense (income), net	972	(3)	999	(287)
Earnings (loss) from continuing operations before taxes	(179)	714	538	2,353
Taxes on earnings (loss) from continuing operations	178	118	240	442
Earnings (loss) from continuing operations	(357)	596	298	1,911
Earnings (loss) from discontinued operations, net of tax	28	(32)	288	(7)
Gain (loss) on sale of discontinued operations, net of tax		16	16	1,752
Net earnings (loss) from discontinued operations, net of tax	28	(16)	304	1,745
Net earnings (loss)	$ (329)	$ 580	$ 602	$ 3,656
Basic Earnings (Loss) Per Common Share -
Continuing operations (in dollars per share)	$ (0.24)	$ 0.40	$ 0.20	$ 1.27
Discontinued operations (in dollars per share)	0.02	(0.01)	0.21	1.16
Net earnings (loss) (in dollars per share)	(0.22)	0.39	0.41	2.43
Diluted Earnings (Loss) Per Common Share -
Continuing operations (in dollars per share)	(0.24)	0.39	0.20	1.26
Discontinued operations (in dollars per share)	0.02	(0.01)	0.20	1.15
Net earnings (loss) (in dollars per share)	(0.22)	0.38	0.40	2.41
Cash Dividends Declared Per Common Share	$ 0.26	$ 0.24	$ 0.78	$ 0.72
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)	1,476,366	1,495,465	1,476,351	1,498,914
Dilutive Common Stock Options (in shares)		9,702	6,329	10,230
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)	1,476,366	1,505,167	1,482,680	1,509,144
Outstanding Common Stock Options Having No Dilutive Effect (in shares)	12,103	717	5,445	658

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Condensed Consolidated Statement of Comprehensive Income
Net Earnings (loss)	$ (329)	$ 580	$ 602	$ 3,656
Foreign currency translation (loss) gain adjustments	89	(645)	406	(1,472)
Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $8 and $5 in 2016 and $14 and $39 in 2015	15	26	(14)	79
Unrealized gains (losses) on marketable equity securities, net of taxes of $(28) and $(28) in 2016 and $(240) and $104 in 2015	613	(1,596)	(143)	(901)
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $(7) and $(31) in 2016 and $2 and $2 in 2015	(27)	8	(124)	9
Other comprehensive income (loss)	690	(2,207)	125	(2,285)
Comprehensive income (loss)	361	$ (1,627)	727	$ 1,371
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments	(4,423)		(4,423)		$ (4,829)
Net actuarial (losses) and prior service cost and credits	(1,972)		(1,972)		(1,958)
Cumulative unrealized (losses) gains on marketable equity securities	(78)		(78)		65
Cumulative (losses) gains on derivative instruments designated as cash flow hedges and other	$ (60)		$ (60)		$ 64

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Condensed Consolidated Statement of Comprehensive Income
Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, taxes	$ 8	$ 14	$ 5	$ 39
Unrealized (losses) gains on marketable equity securities, taxes	(28)	(240)	(28)	104
Net gains (losses) for derivative instruments designated as cash flow hedges and other, taxes	$ (7)	$ 2	$ (31)	$ 2

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheet - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 2,500	$ 5,001
Short-term investments	2,007	1,124
Trade receivables, less allowances of $284 in 2016 and $337 in 2015	3,320	3,418
Inventories:
Finished products	1,763	1,744
Work in process	326	316
Materials	524	539
Total inventories	2,613	2,599
Prepaid expenses and other receivables	1,986	1,908
Current assets held for disposition	552	105
Total Current Assets	12,978	14,155
Investments	2,997	4,041
Property and Equipment, at Cost:
Property and equipment, at cost	12,452	12,383
Less: accumulated depreciation and amortization	6,718	6,653
Net property and equipment	5,734	5,730
Intangible assets, net of amortization	4,674	5,562
Goodwill	7,812	9,638
Deferred income taxes and other assets	2,523	2,119
Non-current assets held for disposition	2,779	2
Total Assets	39,497	41,247
Current Liabilities:
Short-term borrowings	2,531	3,127
Trade accounts payable	1,051	1,081
Salaries, wages and commissions	799	746
Other accrued liabilities	2,715	3,043
Dividends payable	384	383
Income taxes payable	240	430
Current portion of long-term debt	4	3
Current liabilities held for disposition	597	373
Total Current Liabilities	8,321	9,186
Long-term debt	5,975	5,871
Post-employment obligations, deferred income taxes and other long - term Liabilities	4,245	4,864
Non-current liabilities held for disposition	60
Commitments and Contingencies
Shareholders' Investment:
Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued
Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2016: 1,706,957,661; 2015: 1,702,017,390	12,939	12,734
Common shares held in treasury, at cost - Shares: 2016: 234,648,138; 2015: 229,352,338	(10,792)	(10,622)
Earnings employed in the business	25,162	25,757
Accumulated other comprehensive income (loss)	(6,533)	(6,658)
Total Abbott Shareholders' Investment	20,776	21,211
Noncontrolling Interests in Subsidiaries	120	115
Total Shareholders' Investment	20,896	21,326
Total Liabilities and Shareholders' Investment	$ 39,497	$ 41,247

XML 18 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Condensed Consolidated Balance Sheet
Trade receivables, allowances (in dollars)	$ 284	$ 337
Preferred shares, par value (in dollars per share)	$ 1	$ 1
Preferred shares, Authorized shares	1,000,000	1,000,000
Preferred shares, issued shares	0	0
Common shares, Authorized shares	2,400,000,000	2,400,000,000
Common shares, Issued shares	1,706,957,661	1,702,017,390
Common shares held in treasury, shares	234,648,138	229,352,338

XML 19 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash Flow From (Used in) Operating Activities:
Net earnings	$ 602	$ 3,656
Adjustments to reconcile net earnings to net cash from operating activities -
Depreciation	605	648
Amortization of intangible assets	429	458
Share-based compensation	263	249
Impact of currency devaluation	481
Gain on sale of discontinued operations	(25)	(2,837)
Mylan N.V. equity investment adjustment	947
Gain on sale of Mylan N.V. shares		(207)
Trade receivables	(116)	(151)
Inventories	(152)	(213)
Other, net	(1,001)	535
Net Cash From Operating Activities	2,033	2,138
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment	(802)	(862)
Proceeds from business disposition	25	230
Acquisitions of businesses and technologies, net of cash acquired	(73)	(235)
Proceeds from the sale of Mylan N.V. shares		2,290
Sales (Purchases) of other investment securities, net	(982)	(2,626)
Other	34	43
Net Cash (Used in) Investing Activities	(1,798)	(1,160)
Cash Flow From (Used in) Financing Activities:
Net (repayments of) proceeds from issuance of short-term debt and other	(682)	(2,019)
Proceeds from the issuance of long-term debt		2,485
Repayments of long-term debt	(11)	(36)
Payment of debt issuance costs	(170)
Payment of contingent consideration	(25)
Purchases of common shares	(522)	(1,349)
Proceeds from stock options exercised, including income tax benefit	206	263
Dividends paid	(1,153)	(1,083)
Net Cash (Used in) Financing Activities	(2,357)	(1,739)
Effect of exchange rate changes on cash and cash equivalents	(379)	(170)
Net Decrease in Cash and Cash Equivalents	(2,501)	(931)
Cash and Cash Equivalents, Beginning of Year	5,001	4,063
Cash and Cash Equivalents, End of Period	$ 2,500	$ 3,132

XML 20 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2016
Basis of Presentation
Basis of Presentation	Note 1 — Basis of Presentation The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2015. The consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

XML 21 R9.htm IDEA: XBRL DOCUMENT

Discontinued Operations

9 Months Ended

Sep. 30, 2016

Discontinued Operations

Discontinued Operations

Note 2 — Discontinued Operations

The following table summarizes the components of discontinued operations:

	Three Months Ended Sept. 30						Nine Months Ended Sept. 30
(in millions)	2016			2015			2016			2015
Net Sales
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	—		$	—		$	256
AbbVie	—			—			—			—

Total	$	—		$	—		$	—		$	256

Earnings (Loss) Before Tax
Developed markets generics pharmaceuticals and animal health businesses	$	5		$	(6	)	$	(1	)	$	14
AbbVie	—			—			—			—

Total	$	5		$	(6	)	$	(1	)	$	14

Income Tax Expense (Benefit)
Developed markets generics pharmaceuticals and animal health businesses	$	(4	)	$	(1	)	$	(7	)	$	11
AbbVie	(19		)	27			(282		)	10

Total	$	(23	)	$	26		$	(289	)	$	21

Net Earnings (Loss)
Developed markets generics pharmaceuticals and animal health businesses	$	9		$	(5	)	$	6		$	3
AbbVie	19			(27		)	282			(10		)

Total	$	28		$	(32	)	$	288		$	(7	)

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

+ Details

XML 22 R10.htm IDEA: XBRL DOCUMENT

Assets and Liabilities Held for Disposition

9 Months Ended

Sep. 30, 2016

Assets and Liabilities Held for Disposition.

Assets and Liabilities Held for Disposition

Note 3 — Assets and Liabilities Held for Disposition

The following is a summary of the assets and liabilities held for disposition:

(in millions)	September 30, 2016		December 31, 2015
Trade receivables, net	$	226	$	17
Total inventories	247		43
Prepaid expenses and other current assets	79		45

Current assets held for disposition	552		105

Net property and equipment	238		1
Intangible assets, net of amortization	533		—
Goodwill	1,986		—
Deferred income taxes and other assets	22		1

Non-current assets held for disposition	2,779		2

Total assets held for disposition	$	3,331	$	107


Trade accounts payable	$	421	$	359
Salaries, wages, commissions and other accrued liabilities	176		14

Current liabilities held for disposition	597		373
Post-employment obligations, deferred income taxes and other long-term liabilities	60		—

Total liabilities held for disposition	$	657	$	373

XML 23 R11.htm IDEA: XBRL DOCUMENT

Supplemental Financial Information

9 Months Ended

Sep. 30, 2016

Supplemental Financial Information

Supplemental Financial Information

Note 4 — Supplemental Financial Information

The components of long-term investments as of September 30, 2016 and December 31, 2015 are as follows:

(in millions)	September 30,		December 31,
Long-term Investments	2016		2015
Equity securities	$	2,946	$	4,014
Other	51		27

Total	$	2,997	$	4,041

XML 24 R12.htm IDEA: XBRL DOCUMENT

Changes in Accumulated Other Comprehensive Income (Loss)

9 Months Ended

Sep. 30, 2016

Changes in Accumulated Other Comprehensive Income (Loss)

Changes in Accumulated Other Comprehensive Income (Loss)

Note 5 — Changes in Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

	Three Months Ended September 30
	Cumulative Foreign Currency Translation Adjustments						Net Actuarial Losses and Prior Service Costs and Credits						Cumulative Unrealized Gains (Losses) on Marketable Equity Securities						Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
(in millions)	2016			2015			2016			2015			2016			2015			2016			2015
Balance at June 30	$	(4,512	)	$	(3,643	)	$	(1,987	)	$	(2,157	)	$	(691	)	$	696		$	(33	)	$	100

Other comprehensive income (loss) before reclassifications	89			(645		)	—			—			(362		)	(1,596		)	(30		)	41
Amounts reclassified from accumulated other comprehensive income (loss)	—			—			15			26			975			—			3			(33		)

Net current period comprehensive income (loss)	89			(645		)	15			26			613			(1,596		)	(27		)	8

Balance at September 30	$	(4,423	)	$	(4,288	)	$	(1,972	)	$	(2,131	)	$	(78	)	$	(900	)	$	(60	)	$	108

	Nine Months Ended September 30
	Cumulative Foreign Currency Translation Adjustments						Net Actuarial Losses and Prior Service Costs and Credits						Cumulative Unrealized Gains (Losses) on Marketable Equity Securities						Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
(in millions)	2016			2015			2016			2015			2016			2015			2016			2015
Balance at December 31, 2015 and 2014	$	(4,829	)	$	(2,924	)	$	(1,958	)	$	(2,229	)	$	65		$	1		$	64		$	99

Impact of business dispositions	—			108			—			19			—			—			—			—

Other comprehensive income (loss) before reclassifications	406			(1,472		)	(62		)	—			(1,118		)	(763		)	(77		)	89
Amounts reclassified from accumulated other comprehensive income (loss)	—			—			48			79			975			(138		)	(47		)	(80		)

Net current period comprehensive income (loss)	406			(1,472		)	(14		)	79			(143		)	(901		)	(124		)	9

Balance at September 30	$	(4,423	)	$	(4,288	)	$	(1,972	)	$	(2,131	)	$	(78	)	$	(900	)	$	(60	)	$	108

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

XML 25 R13.htm IDEA: XBRL DOCUMENT

Business Acquisitions	9 Months Ended
Business Acquisitions	Sep. 30, 2016
Business Acquisitions
Business Acquisitions	Note 6 — Business Acquisitions In August 2015, Abbott completed the acquisition of the equity of Tendyne Holdings, Inc. (Tendyne) that Abbott did not already own for approximately $225 million in cash plus additional payments up to $150 million to be made upon completion of certain regulatory milestones. The acquisition of Tendyne, which is focused on developing minimally invasive mitral valve replacement therapies, allows Abbott to broaden its foundation in the treatment of mitral valve disease. The final allocation of the fair value of the acquisition resulted in non-deductible acquired in-process research and development of approximately $220 million, which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation, non-deductible goodwill of approximately $142 million, deferred tax assets and other net assets of approximately $18 million, deferred tax liabilities of approximately $85 million, and contingent consideration of approximately $70 million. The goodwill is identifiable to the Vascular Products segment. Had this acquisition taken place as of the beginning of the comparable prior annual reporting period, consolidated net sales and earnings would not have been significantly different from reported amounts. On January 30, 2016, Abbott entered into a definitive agreement to acquire Alere Inc. (Alere). With annual sales of approximately $2.5 billion, Alere is a global leader in point of care diagnostics. The acquisition, which is expected to significantly advance Abbott’s global diagnostics presence and leadership, is subject to the approval of Alere shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. On May 2, 2016, Abbott and Alere received a request for additional information from the United States Federal Trade Commission (FTC) relating to Abbott’s potential acquisition of Alere. The effect of this request, which was issued under the Hart-Scott Rodino (HSR) Antitrust Improvements Act of 1976, as amended, is to extend the waiting period imposed by the HSR Act until 30 days after Abbott and Alere have substantially complied with this request, unless the period is extended voluntarily by the parties or terminated sooner by the FTC. On August 25, 2016, Alere filed a lawsuit against Abbott alleging that Abbott had breached its obligations under the agreement in connection with obtaining regulatory approvals. Abbott denies Alere’s allegations in the case. Abbott has complied with all of its obligations under the agreement. On October 21, 2016, Alere shareholders approved the acquisition. Under the terms of the agreement, Abbott will pay $56 per common share at a total expected equity value of $5.8 billion. Alere’s net debt, currently $2.5 billion, will be assumed or refinanced by Abbott. In February 2016, Abbott obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed $9 billion in conjunction with its pending acquisition of Alere. While Abbott plans to use cash on hand at the time of the acquisition from anticipated long-term borrowings to acquire Alere, the bridge facility will provide back-up financing. On April 27, 2016, Abbott entered into a definitive agreement to acquire St. Jude Medical, Inc. (St. Jude Medical). With 2015 sales of approximately $5.5 billion, St. Jude Medical is a global medical device manufacturer. The acquisition, which is expected to significantly advance Abbott’s global cardiovascular device presence and leadership, is subject to the approval of St. Jude Medical shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. On July 11, 2016, Abbott and St. Jude Medical received a request for additional information from the FTC relating to Abbott’s potential acquisition of St. Jude Medical. The effect of this request, which was issued under the HSR Act, is to extend the waiting period imposed by the HSR Act until 30 days after Abbott and St. Jude Medical have substantially complied with this request, unless the period is extended voluntarily by the parties or terminated sooner by the FTC. On October 18, 2016, Abbott and St. Jude Medical announced an agreement to sell certain products to Terumo Corporation (Terumo). The transaction with Terumo reflects a purchase price of approximately $1.12 billion and is subject to the successful completion of Abbott’s acquisition of St. Jude Medical and antitrust regulatory approvals. On October 26, 2016, St. Jude Medical shareholders approved the acquisition. Under the terms of the agreement, for each share of stock, St. Jude Medical shareholders will receive $46.75 in cash and 0.8708 of a share of Abbott common stock. At an Abbott stock price of $40.74, which reflects the closing price on October 20, 2016, this represents a value of approximately $82 per common share at a total expected equity value of approximately $24 billion. St. Jude Medical’s net debt of approximately $5.4 billion will be assumed or refinanced by Abbott. In April 2016, Abbott obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed $17.2 billion in conjunction with its pending acquisition of St. Jude Medical. While Abbott plans to fund the cash portion of this transaction with anticipated medium and long-term borrowings, the bridge facility will provide back-up financing.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 26 R14.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets	9 Months Ended
Goodwill and Intangible Assets	Sep. 30, 2016
Goodwill and Intangible Assets
Goodwill and Intangible Assets	Note 7 — Goodwill and Intangible Assets The total amount of goodwill reported was $7.812 billion at September 30, 2016 and $9.638 billion at December 31, 2015. The amount at September 30, 2016 excludes goodwill included in non-current assets held for disposition. In the third quarter of 2016, approximately $2.0 billion of goodwill was moved to Non-current assets held for disposition due to the pending sale of AMO. In the first nine months of 2016, foreign currency translation adjustments increased goodwill by approximately $126 million. There were no purchase price allocation adjustments associated with recent acquisitions made during the nine months of 2016. The amount of goodwill related to reportable segments at September 30, 2016 was $3.0 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $451 million for the Diagnostic Products segment, and $3.1 billion for the Vascular Products segment. There was no reduction of goodwill relating to impairments. The gross amount of amortizable intangible assets, primarily product rights and technology was $10.5 billion as of September 30, 2016 and $10.8 billion as of December 31, 2015, and accumulated amortization was $6.1 billion as of September 30, 2016 and $5.7 billion as of December 31, 2015. The September 30, 2016 amounts exclude the intangibles included in Non-current assets held for disposition. In the third quarter of 2016, approximately $533 million of net intangible assets related to AMO was moved to Non-current assets held for disposition due to the pending sale of this business. Foreign currency translation adjustments increased intangible assets by $72 million in the first nine months of 2016. Indefinite-lived intangible assets, which relate to in-process research and development acquired in a business combination, were approximately $325 million and $419 million as of September 30, 2016 and December 31, 2015, respectively. In the first nine months of 2016, Abbott recorded an impairment of a $59 million in-process research and development project related to a non-reportable segment. Abbott’s estimated annual amortization expense for intangible assets is approximately $560 million in 2016, $490 million in 2017, $450 million in 2018, $420 million in 2019 and $410 million in 2020. Amortizable intangible assets are amortized over 2 to 20 years (weighted average 13 years).

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 27 R15.htm IDEA: XBRL DOCUMENT

Restructuring Plans

9 Months Ended

Sep. 30, 2016

Restructuring Plans

Restructuring Plans

Note 8 — Restructuring Plans

(in millions)
Accrued balance at December 31, 2015	$	100
Restructuring charges recorded in 2016	23
Payments and other adjustments	(47		)

Accrued balance at September 30, 2016	$	76

(in millions)
Accrued balance at December 31, 2015	$	88
Restructuring charges recorded in 2016	12
Payments and other adjustments	(65		)

Accrued balance at September 30, 2016	$	35

(in millions)
Accrued balance at December 31, 2015	$	11
Payments and other adjustments	(6		)

Accrued balance at September 30, 2016	$	5

XML 28 R16.htm IDEA: XBRL DOCUMENT

Incentive Stock Programs

9 Months Ended

Sep. 30, 2016

Incentive Stock Programs

Incentive Stock Programs

Note 9 — Incentive Stock Programs

	Outstanding		Exercisable
Number of shares	36,376,374		23,861,634
Weighted average remaining life (years)	5.4		3.7
Weighted average exercise price	$	34.01	$	30.36
Aggregate intrinsic value (in millions)	$	328	$	294

The total unrecognized share-based compensation cost at September 30, 2016 amounted to approximately $237 million which is expected to be recognized over the next three years.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 29 R17.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures

9 Months Ended

Sep. 30, 2016

Financial Instruments, Derivatives and Fair Value Measures

Financial Instruments, Derivatives and Fair Value Measures

Note 10 — Financial Instruments, Derivatives and Fair Value Measures

The following table summarizes the amounts and location of certain derivative financial instruments as of September 30, 2016 and December 31, 2015:

	Fair Value - Assets					Fair Value - Liabilities
(in millions)	Sept. 30, 2016		Dec. 31, 2015		Balance Sheet Caption	Sept. 30, 2016		Dec. 31, 2015		Balance Sheet Caption
Interest rate swaps designated as fair value hedges	$	211	$	116	Deferred income taxes and other assets	$	—	$	—	n/a

Foreign currency forward exchange contracts:
Hedging instruments	28		64		Prepaid expenses and other receivables	97		18		Other accrued liabilities
Others not designated as hedges	122		115		Prepaid expenses and other receivables	59		84		Other accrued liabilities

Debt designated as a hedge of net investment in a foreign subsidiary	—		—		n/a	522		439		Short-term borrowings

	$	361	$	295		$	678	$	541

	Gain (loss) Recognized in Other Comprehensive Income (loss)											Income (expense) and Gain (loss) Reclassified into Income
	Three Months Ended Sept. 30						Nine Months Ended Sept. 30					Three Months Ended Sept. 30					Nine Months Ended Sept. 30				Income Statement
(in millions)	2016			2015			2016			2015		2016			2015		2016		2015		Caption

Foreign currency forward exchange contracts designated as cash flow hedges	$	(45	)	$	41		$	(96	)	$	89	$	5		$	33	$	59	$	80	Cost of products sold

Debt designated as a hedge of net investment in a foreign subsidiary	(6		)	(11		)	(83		)	3		n/a			n/a		n/a		n/a		n/a

Interest rate swaps designated as fair value hedges	n/a			n/a			n/a			n/a		(50		)	85		95		71		Interest expense

	September 30, 2016						December 31, 2015
(in millions)	Carrying Value			Fair Value			Carrying Value			Fair Value
Investment Securities:
Equity securities	$	2,946		$	2,946		$	4,014		$	4,014
Other	51			55			27			30
Total Long-term Debt	(5,979		)	(6,665		)	(5,874		)	(6,337		)
Foreign Currency Forward Exchange Contracts:
Receivable position	150			150			179			179
(Payable) position	(156		)	(156		)	(102		)	(102		)
Interest Rate Hedge Contracts:
Receivable position	211			211			116			116

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

			Basis of Fair Value Measurement
(in millions)	Outstanding Balances		Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
September 30, 2016:
Equity securities	$	2,675	$	2,675	$	—	$	—
Interest rate swap derivative financial instruments	211		—		211		—
Foreign currency forward exchange contracts	150		—		150		—

Total Assets	$	3,036	$	2,675	$	361	$	—


Fair value of hedged long-term debt	$	4,238	$	—	$	4,238	$	—
Foreign currency forward exchange contracts	156		—		156		—
Contingent consideration related to business combinations	163		—		—		163

Total Liabilities	$	4,557	$	—	$	4,394	$	163


December 31, 2015:
Equity securities	$	3,780	$	3,780	$	—	$	—
Interest rate swap derivative financial instruments	116		—		116		—
Foreign currency forward exchange contracts	179		—		179		—

Total Assets	$	4,075	$	3,780	$	295	$	—


Fair value of hedged long-term debt	$	4,135	$	—	$	4,135	$	—
Foreign currency forward exchange contracts	102		—		102		—
Contingent consideration related to business combinations	173		—		—		173

Total Liabilities	$	4,410	$	—	$	4,237	$	173

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

XML 30 R18.htm IDEA: XBRL DOCUMENT

Litigation and Environmental Matters	9 Months Ended
Litigation and Environmental Matters	Sep. 30, 2016
Litigation and Environmental Matters
Litigation and Environmental Matters	Note 11 — Litigation and Environmental Matters Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million. Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $40 million to $45 million. The recorded accrual balance at September 30, 2016 for these proceedings and exposures was approximately $45 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

XML 31 R19.htm IDEA: XBRL DOCUMENT

Post-Employment Benefits

9 Months Ended

Sep. 30, 2016

Post-Employment Benefits

Post-Employment Benefits

Note 12 — Post-Employment Benefits

	Defined Benefit Plans												Medical and Dental Plans
	Three Months						Nine Months						Three Months						Nine Months
	Ended Sept. 30						Ended Sept. 30						Ended Sept. 30						Ended Sept. 30
(in millions)	2016			2015			2016			2015			2016			2015			2016			2015
Service cost - benefits earned during the period	$	66		$	80		$	200		$	230		$	7		$	9		$	20		$	24
Interest cost on projected benefit obligations	72			78			218			234			11			14			33			39
Expected return on plan assets	(142		)	(128		)	(426		)	(385		)	(9		)	(10		)	(26		)	(29		)
Net amortization of:
Actuarial loss, net	34			47			97			136			4			8			13			18
Prior service cost (credit)	—			—			—			—			(12		)	(12		)	(34		)	(36		)

Total cost	30			77			89			215			1			9			6			16
Less: Discontinued operations	—			—			—			1			—			—			—			—

Net cost - continuing operations	$	30		$	77		$	89		$	214		$	1		$	9		$	6		$	16

XML 32 R20.htm IDEA: XBRL DOCUMENT

Taxes on Earnings	9 Months Ended
Taxes on Earnings	Sep. 30, 2016
Taxes on Earnings
Taxes on Earnings	Note 13 — Taxes on Earnings Taxes on earnings from continuing operations reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2016, taxes on earnings from continuing operations includes the impact of a net tax benefit of approximately $250 million as a result of the resolution of various tax positions from prior years, partially offset by the unfavorable impact of non-deductible foreign exchange losses related to Venezuela and the adjustment of the Mylan N.V. equity investment as well as the recognition of deferred taxes associated with the pending sale of AMO. Earnings from discontinued operations, net of tax, in the first nine months of 2016 reflects the recognition of $289 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately $546 million. In the first nine months of 2015, taxes on earnings from continuing operations include a tax cost of $71 million related to the disposal of shares of Mylan N.V. stock. Taxes on earnings from continuing operations in the first nine months of 2015 were not affected by any adjustments as the result of the resolution of various tax positions pertaining to prior years. 2015 tax expense related to discontinued operations includes $667 million of tax expense on certain funds earned outside the U.S. in 2015 that were not designated as permanently reinvested overseas. Earnings from discontinued operations, net of tax, in the first nine months of 2015 also reflects the recognition of $10 million of net tax expense primarily as a result of the resolution of various tax positions related to AbbVie’s operations for years prior to the separation. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately $16 million. Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease by $100 million to $200 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., Abbott’s federal income tax returns through 2013 are settled except for one issue.

XML 33 R21.htm IDEA: XBRL DOCUMENT

Segment Information

9 Months Ended

Sep. 30, 2016

Segment Information

Segment Information

Note 14 — Segment Information

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions are aggregated and reported as the Diagnostic Products segment.

Vascular Products — Worldwide sales of coronary, endovascular, structural heart, vessel closure and other medical device products. For segment reporting purposes, the Vascular and Electrophysiology Products divisions are aggregated and reported as the Vascular Products segment.

Non-reportable segments include the Diabetes Care and Medical Optics segments.

	Net Sales to External Customers								Operating Earnings
	Three Months				Nine Months				Three Months						Nine Months
	Ended Sept. 30				Ended Sept. 30				Ended Sept. 30						Ended Sept. 30
(in millions)	2016		2015		2016		2015		2016			2015			2016			2015
Established Pharmaceutical Products	$	1,012	$	961	$	2,880	$	2,835	$	211		$	177		$	551		$	516
Nutritional Products	1,755		1,789		5,166		5,175		438			459			1,148			1,198
Diagnostic Products	1,213		1,156		3,557		3,426		301			307			856			887
Vascular Products	708		672		2,175		2,092		249			239			786			803

Total Reportable Segments	4,688		4,578		13,778		13,528		1,199			1,182			3,341			3,404
Other	614		572		1,742		1,689

Net Sales	$	5,302	$	5,150	$	15,520	$	15,217

Corporate functions and benefit plans costs									(107		)	(109		)	(282		)	(330		)
Non-reportable segments									105			76			155			193
Net interest expense (a)									(95		)	(16		)	(203		)	(49		)
Share-based compensation (b)									(49		)	(43		)	(263		)	(248		)
Amortization of intangible assets									(140		)	(151		)	(429		)	(458		)
Other, net (c)									(1,092		)	(225		)	(1,781		)	(159		)

Earnings (loss) from continuing operations before taxes									$	(179	)	$	714		$	538		$	2,353

(a)

Net interest expense for the quarter and the nine months ended September 30, 2016 includes amortization expense associated with bridge facility fees.

(b)

Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(c)

Other, net for the nine months ended September 30, 2016, includes the $947 million adjustment of the Mylan equity investment and $481 million of foreign currency loss related to operations in Venezuela. Other, net for the nine months ended September 30, 2015, includes a gain on the sale of a portion of Abbott’s position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

XML 34 R22.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Tables)

9 Months Ended

Sep. 30, 2016

Discontinued Operations

Components of discontinued operations

	Three Months Ended Sept. 30						Nine Months Ended Sept. 30
(in millions)	2016			2015			2016			2015
Net Sales
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	—		$	—		$	256
AbbVie	—			—			—			—

Total	$	—		$	—		$	—		$	256

Earnings (Loss) Before Tax
Developed markets generics pharmaceuticals and animal health businesses	$	5		$	(6	)	$	(1	)	$	14
AbbVie	—			—			—			—

Total	$	5		$	(6	)	$	(1	)	$	14

Income Tax Expense (Benefit)
Developed markets generics pharmaceuticals and animal health businesses	$	(4	)	$	(1	)	$	(7	)	$	11
AbbVie	(19		)	27			(282		)	10

Total	$	(23	)	$	26		$	(289	)	$	21

Net Earnings (Loss)
Developed markets generics pharmaceuticals and animal health businesses	$	9		$	(5	)	$	6		$	3
AbbVie	19			(27		)	282			(10		)

Total	$	28		$	(32	)	$	288		$	(7	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

XML 35 R23.htm IDEA: XBRL DOCUMENT

Assets and Liabilities Held for Disposition (Tables)

9 Months Ended

Sep. 30, 2016

Assets and Liabilities Held for Disposition.

Summary of the assets and liabilities held for disposition

(in millions)	September 30, 2016		December 31, 2015
Trade receivables, net	$	226	$	17
Total inventories	247		43
Prepaid expenses and other current assets	79		45

Current assets held for disposition	552		105

Net property and equipment	238		1
Intangible assets, net of amortization	533		—
Goodwill	1,986		—
Deferred income taxes and other assets	22		1

Non-current assets held for disposition	2,779		2

Total assets held for disposition	$	3,331	$	107


Trade accounts payable	$	421	$	359
Salaries, wages, commissions and other accrued liabilities	176		14

Current liabilities held for disposition	597		373
Post-employment obligations, deferred income taxes and other long-term liabilities	60		—

Total liabilities held for disposition	$	657	$	373

XML 36 R24.htm IDEA: XBRL DOCUMENT

Supplemental Financial Information (Tables)

9 Months Ended

Sep. 30, 2016

Supplemental Financial Information

Components of long-term investments

(in millions)	September 30,		December 31,
Long-term Investments	2016		2015
Equity securities	$	2,946	$	4,014
Other	51		27

Total	$	2,997	$	4,041

XML 37 R25.htm IDEA: XBRL DOCUMENT

Changes in Accumulated Other Comprehensive Income (Loss) (Tables)

9 Months Ended

Sep. 30, 2016

Changes in Accumulated Other Comprehensive Income (Loss)

Schedule of Accumulated Other Comprehensive Income (Loss)

	Three Months Ended September 30
	Cumulative Foreign Currency Translation Adjustments						Net Actuarial Losses and Prior Service Costs and Credits						Cumulative Unrealized Gains (Losses) on Marketable Equity Securities						Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
(in millions)	2016			2015			2016			2015			2016			2015			2016			2015
Balance at June 30	$	(4,512	)	$	(3,643	)	$	(1,987	)	$	(2,157	)	$	(691	)	$	696		$	(33	)	$	100

Other comprehensive income (loss) before reclassifications	89			(645		)	—			—			(362		)	(1,596		)	(30		)	41
Amounts reclassified from accumulated other comprehensive income (loss)	—			—			15			26			975			—			3			(33		)

Net current period comprehensive income (loss)	89			(645		)	15			26			613			(1,596		)	(27		)	8

Balance at September 30	$	(4,423	)	$	(4,288	)	$	(1,972	)	$	(2,131	)	$	(78	)	$	(900	)	$	(60	)	$	108

	Nine Months Ended September 30
	Cumulative Foreign Currency Translation Adjustments						Net Actuarial Losses and Prior Service Costs and Credits						Cumulative Unrealized Gains (Losses) on Marketable Equity Securities						Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
(in millions)	2016			2015			2016			2015			2016			2015			2016			2015
Balance at December 31, 2015 and 2014	$	(4,829	)	$	(2,924	)	$	(1,958	)	$	(2,229	)	$	65		$	1		$	64		$	99

Impact of business dispositions	—			108			—			19			—			—			—			—

Other comprehensive income (loss) before reclassifications	406			(1,472		)	(62		)	—			(1,118		)	(763		)	(77		)	89
Amounts reclassified from accumulated other comprehensive income (loss)	—			—			48			79			975			(138		)	(47		)	(80		)

Net current period comprehensive income (loss)	406			(1,472		)	(14		)	79			(143		)	(901		)	(124		)	9

Balance at September 30	$	(4,423	)	$	(4,288	)	$	(1,972	)	$	(2,131	)	$	(78	)	$	(900	)	$	(60	)	$	108

XML 38 R26.htm IDEA: XBRL DOCUMENT

Restructuring Plans (Tables)

9 Months Ended

Sep. 30, 2016

Restructuring Plan 2016, 2015 and 2014

Restructuring costs

Schedule of restructuring activity

(in millions)
Accrued balance at December 31, 2015	$	100
Restructuring charges recorded in 2016	23
Payments and other adjustments	(47		)

Accrued balance at September 30, 2016	$	76

Restructuring Plan 2013 to 2015

Restructuring costs

Schedule of restructuring activity

(in millions)
Accrued balance at December 31, 2015	$	88
Restructuring charges recorded in 2016	12
Payments and other adjustments	(65		)

Accrued balance at September 30, 2016	$	35

Restructuring Plan 2013 and Prior Years

Restructuring costs

Schedule of restructuring activity

(in millions)
Accrued balance at December 31, 2015	$	11
Payments and other adjustments	(6		)

Accrued balance at September 30, 2016	$	5

XML 39 R27.htm IDEA: XBRL DOCUMENT

Incentive Stock Programs (Tables)

9 Months Ended

Sep. 30, 2016

Incentive Stock Programs

Stock options outstanding and exercisable

	Outstanding		Exercisable
Number of shares	36,376,374		23,861,634
Weighted average remaining life (years)	5.4		3.7
Weighted average exercise price	$	34.01	$	30.36
Aggregate intrinsic value (in millions)	$	328	$	294

XML 40 R28.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures (Tables)

9 Months Ended

Sep. 30, 2016

Financial Instruments, Derivatives and Fair Value Measures

Summary of the amounts and location of certain derivative financial instruments

	Fair Value - Assets					Fair Value - Liabilities
(in millions)	Sept. 30, 2016		Dec. 31, 2015		Balance Sheet Caption	Sept. 30, 2016		Dec. 31, 2015		Balance Sheet Caption
Interest rate swaps designated as fair value hedges	$	211	$	116	Deferred income taxes and other assets	$	—	$	—	n/a

Foreign currency forward exchange contracts:
Hedging instruments	28		64		Prepaid expenses and other receivables	97		18		Other accrued liabilities
Others not designated as hedges	122		115		Prepaid expenses and other receivables	59		84		Other accrued liabilities

Debt designated as a hedge of net investment in a foreign subsidiary	—		—		n/a	522		439		Short-term borrowings

	$	361	$	295		$	678	$	541

Schedule of derivatives gain (loss) in OCI and earnings

	Gain (loss) Recognized in Other Comprehensive Income (loss)											Income (expense) and Gain (loss) Reclassified into Income
	Three Months Ended Sept. 30						Nine Months Ended Sept. 30					Three Months Ended Sept. 30					Nine Months Ended Sept. 30				Income Statement
(in millions)	2016			2015			2016			2015		2016			2015		2016		2015		Caption

Foreign currency forward exchange contracts designated as cash flow hedges	$	(45	)	$	41		$	(96	)	$	89	$	5		$	33	$	59	$	80	Cost of products sold

Debt designated as a hedge of net investment in a foreign subsidiary	(6		)	(11		)	(83		)	3		n/a			n/a		n/a		n/a		n/a

Interest rate swaps designated as fair value hedges	n/a			n/a			n/a			n/a		(50		)	85		95		71		Interest expense

Schedule of carrying values and fair values of certain financial instruments

	September 30, 2016						December 31, 2015
(in millions)	Carrying Value			Fair Value			Carrying Value			Fair Value
Investment Securities:
Equity securities	$	2,946		$	2,946		$	4,014		$	4,014
Other	51			55			27			30
Total Long-term Debt	(5,979		)	(6,665		)	(5,874		)	(6,337		)
Foreign Currency Forward Exchange Contracts:
Receivable position	150			150			179			179
(Payable) position	(156		)	(156		)	(102		)	(102		)
Interest Rate Hedge Contracts:
Receivable position	211			211			116			116

Schedule of assets and liabilities measured at fair value on a recurring basis

			Basis of Fair Value Measurement
(in millions)	Outstanding Balances		Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
September 30, 2016:
Equity securities	$	2,675	$	2,675	$	—	$	—
Interest rate swap derivative financial instruments	211		—		211		—
Foreign currency forward exchange contracts	150		—		150		—

Total Assets	$	3,036	$	2,675	$	361	$	—


Fair value of hedged long-term debt	$	4,238	$	—	$	4,238	$	—
Foreign currency forward exchange contracts	156		—		156		—
Contingent consideration related to business combinations	163		—		—		163

Total Liabilities	$	4,557	$	—	$	4,394	$	163


December 31, 2015:
Equity securities	$	3,780	$	3,780	$	—	$	—
Interest rate swap derivative financial instruments	116		—		116		—
Foreign currency forward exchange contracts	179		—		179		—

Total Assets	$	4,075	$	3,780	$	295	$	—


Fair value of hedged long-term debt	$	4,135	$	—	$	4,135	$	—
Foreign currency forward exchange contracts	102		—		102		—
Contingent consideration related to business combinations	173		—		—		173

Total Liabilities	$	4,410	$	—	$	4,237	$	173

XML 41 R29.htm IDEA: XBRL DOCUMENT

Post-Employment Benefits (Tables)

9 Months Ended

Sep. 30, 2016

Post-Employment Benefits

The components of the net periodic benefit cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans

	Defined Benefit Plans												Medical and Dental Plans
	Three Months						Nine Months						Three Months						Nine Months
	Ended Sept. 30						Ended Sept. 30						Ended Sept. 30						Ended Sept. 30
(in millions)	2016			2015			2016			2015			2016			2015			2016			2015
Service cost - benefits earned during the period	$	66		$	80		$	200		$	230		$	7		$	9		$	20		$	24
Interest cost on projected benefit obligations	72			78			218			234			11			14			33			39
Expected return on plan assets	(142		)	(128		)	(426		)	(385		)	(9		)	(10		)	(26		)	(29		)
Net amortization of:
Actuarial loss, net	34			47			97			136			4			8			13			18
Prior service cost (credit)	—			—			—			—			(12		)	(12		)	(34		)	(36		)

Total cost	30			77			89			215			1			9			6			16
Less: Discontinued operations	—			—			—			1			—			—			—			—

Net cost - continuing operations	$	30		$	77		$	89		$	214		$	1		$	9		$	6		$	16

XML 42 R30.htm IDEA: XBRL DOCUMENT

Segment Information (Tables)

9 Months Ended

Sep. 30, 2016

Segment Information

Schedule of segment information - net sales and operating earnings

	Net Sales to External Customers								Operating Earnings
	Three Months				Nine Months				Three Months						Nine Months
	Ended Sept. 30				Ended Sept. 30				Ended Sept. 30						Ended Sept. 30
(in millions)	2016		2015		2016		2015		2016			2015			2016			2015
Established Pharmaceutical Products	$	1,012	$	961	$	2,880	$	2,835	$	211		$	177		$	551		$	516
Nutritional Products	1,755		1,789		5,166		5,175		438			459			1,148			1,198
Diagnostic Products	1,213		1,156		3,557		3,426		301			307			856			887
Vascular Products	708		672		2,175		2,092		249			239			786			803

Total Reportable Segments	4,688		4,578		13,778		13,528		1,199			1,182			3,341			3,404
Other	614		572		1,742		1,689

Net Sales	$	5,302	$	5,150	$	15,520	$	15,217

Corporate functions and benefit plans costs									(107		)	(109		)	(282		)	(330		)
Non-reportable segments									105			76			155			193
Net interest expense (a)									(95		)	(16		)	(203		)	(49		)
Share-based compensation (b)									(49		)	(43		)	(263		)	(248		)
Amortization of intangible assets									(140		)	(151		)	(429		)	(458		)
Other, net (c)									(1,092		)	(225		)	(1,781		)	(159		)

Earnings (loss) from continuing operations before taxes									$	(179	)	$	714		$	538		$	2,353

(a)

Net interest expense for the quarter and the nine months ended September 30, 2016 includes amortization expense associated with bridge facility fees.

(b)

Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(c)

XML 43 R31.htm IDEA: XBRL DOCUMENT

Discontinued Operations - (Details) - USD ($) shares in Thousands, $ in Millions			1 Months Ended	3 Months Ended			9 Months Ended
	Feb. 27, 2015	Feb. 10, 2015	Apr. 30, 2015	Mar. 31, 2016	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
After Tax Gain					$ 16		$ 16	$ 1,752
Gain on sale of Mylan shares								207
Proceeds from the sale of Mylan N.V. shares								2,290
Proceeds from the disposition of business							$ 25	230
Developed markets branded generics pharmaceuticals business
Value of shares received for sale of generics pharmaceuticals business to Mylan Inc	$ 5,770
After Tax Gain	$ 1,600
Developed markets branded generics pharmaceuticals business \| Minimum
Period for providing manufacturing supply of products	3 years
Developed markets branded generics pharmaceuticals business \| Maximum
Period of transition services	2 years
Period for providing manufacturing supply of products	10 years
Period of notice require to terminate manufacturing supply of products	2 years
Animal Health Business
After Tax Gain		$ 130		$ 16
Proceeds from the disposition of business		$ 230		$ 25
Mylan
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc			110,000
Number of shares in investment sold			40,250
Gain on sale of Mylan shares						$ 207
Proceeds from the sale of Mylan N.V. shares						$ 2,290
Mylan \| Developed markets branded generics pharmaceuticals business
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc	110,000
Percentage of shares received for sale of generics pharmaceuticals business to Mylan Inc	22.00%
Proceeds from the sale of Mylan N.V. shares								$ 2,290
Mylan NV
Ownership interest (as a percent)			14.00%		14.00%			14.00%
Mylan NV \| Developed markets branded generics pharmaceuticals business
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc								110,000
Number of shares in investment sold								40,250
Gain on sale of Mylan shares								$ 207

XML 44 R32.htm IDEA: XBRL DOCUMENT

Discontinued Operations - AbbVie Separation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Net sales				$ 256
Earnings (Loss) Before Tax	$ 5	$ (6)	$ (1)	14
Income Tax Expense (Benefit)	(23)	26	(289)	21
Net Earnings (Loss)	28	(32)	288	(7)
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
Pretax Gain			25	2,837
Tax Expenses from discontinued operations				1,100
After Tax Gain		16	16	1,752
Developed Markets Generics Pharmaceuticals And Animal Health Business
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Net sales				256
Earnings (Loss) Before Tax	5	(6)	(1)	14
Income Tax Expense (Benefit)	(4)	(1)	(7)	11
Net Earnings (Loss)	9	(5)	6	3
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
Pretax Gain				2,837
Tax Expenses from discontinued operations				1,085
After Tax Gain				1,752
AbbVie
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Income Tax Expense (Benefit)	(19)	27	(282)	10
Net Earnings (Loss)	19	$ (27)	282	$ (10)
AbbVie \| Proprietary Pharmaceuticals Business Assets and Liabilities Held for Disposal
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Prepaid asset	$ 306		$ 306

XML 45 R33.htm IDEA: XBRL DOCUMENT

Assets and Liabilities Held for Disposition (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2017
Discontinued Operations.
Earnings (loss) before taxes	$ (179)	$ 714	$ 538	$ 2,353
AMO \| Dispositions held for sale
Discontinued Operations.
Earnings (loss) before taxes	$ 2	$ (2)	$ (42)	$ 54
AMO \| Dispositions held for sale \| Forecast
Discontinued Operations.
Sale consideration					$ 4,325

XML 46 R34.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Assets And Liabilities Held For Disposition (Details) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Assets and Liabilities Held for Disposition.
Trade receivables, net	$ 226	$ 17
Total inventories	247	43
Prepaid expenses and other current assets	79	45
Current assets held for disposition	552	105
Net property and equipment	238	1
Intangible assets, net of amortization	533
Goodwill	1,986
Deferred income taxes and other assets	22	1
Non-current assets held for disposition	2,779	2
Total assets held for disposition	3,331	107
Trade accounts payable	421	359
Salaries, wages, commissions and other accrued liabilities	176	14
Current liabilities held for disposition	597	373
Post-employment obligations, deferred income taxes and other long-term liabilities	60
Total liabilities held for disposition	$ 657	$ 373

XML 47 R35.htm IDEA: XBRL DOCUMENT

Supplemental Financial Information (Details). shares in Thousands, $ in Millions			1 Months Ended	3 Months Ended			9 Months Ended
	Sep. 30, 2016 USD ($)	Feb. 27, 2015 shares	Apr. 30, 2015 shares	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($) shares	Mar. 31, 2016	Feb. 17, 2016	Feb. 16, 2016	Dec. 31, 2015 USD ($)
Net earnings
Earnings (loss) from continuing operations allocated to common shares				$ (357)	$ 593		$ 297	$ 1,902
Net earnings (loss) allocated to common shares				(329)	$ 577		600	3,638
Mylan N.V. equity investment adjustment	$ 947						947
Gain on sale of Mylan N.V. shares								207
Proceeds from the sale of Mylan N.V. shares								2,290
Post-employment Obligations and Other Long-term Liabilities:
Noncash impact of tax benefits from resolution of prior year tax positions							539
Non-cash impact of tax expense associated with the gain on the sale of businesses								$ 1,100
Investments
Investments	$ 2,997			$ 2,997			2,997					$ 4,041
Currency exchange rates
Foreign currency loss on remeasurement							481
Mylan
Net earnings
Gain on sale of Mylan N.V. shares						$ 207
Number of shares in investment sold \| shares			40,250
Proceeds from the sale of Mylan N.V. shares						$ 2,290
Investments
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc \| shares			110,000
Mylan NV
Net earnings
Remaining ownership interest ( as percentage)			14.00%		14.00%			14.00%
Venezuela
Post-employment Obligations and Other Long-term Liabilities:
Cash impact from foreign currency loss							$ 410
Investments
Abbott's total net assets from Venezuelan operations (as a percent)	0.10%			0.10%			0.10%
Currency exchange rates
Foreign currency loss on remeasurement							$ 481
Venezuelan bolivars
Currency exchange rates
Official rate to U.S. dollar												6.3
CENCOEX
Currency exchange rates
Official rate to U.S. dollar												6.3
SICAD
Currency exchange rates
Official rate to U.S. dollar												13.5
SIMADI
Currency exchange rates
Official rate to U.S. dollar												200
DIPRO
Currency exchange rates
Official rate to U.S. dollar										10	6.3
DICOM
Currency exchange rates
Official rate to U.S. dollar									263
Defined Benefit Plans
Post-employment Obligations and Other Long-term Liabilities:
Company contributions							540	$ 551
Medical and Dental Plans
Post-employment Obligations and Other Long-term Liabilities:
Company contributions							9	24
Equity securities
Investments
Investments	$ 2,946			$ 2,946			2,946					$ 4,014
Other,
Investments
Investments	$ 51			$ 51			51					$ 27
Developed markets branded generics pharmaceuticals business
Post-employment Obligations and Other Long-term Liabilities:
Cash impact of tax benefits from resolution of prior year tax positions							$ 140
Developed markets branded generics pharmaceuticals business \| Mylan
Net earnings
Decrease in fair value of contingent consideration								79
Proceeds from the sale of Mylan N.V. shares								2,290
Investments
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc \| shares		110,000
Developed markets branded generics pharmaceuticals business \| Mylan NV
Net earnings
Gain on sale of Mylan N.V. shares								$ 207
Number of shares in investment sold \| shares								40,250
Investments
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc \| shares								110,000
Percentage of shares held before sale of generics pharmaceuticals business to Mylan Inc								22.00%

XML 48 R36.htm IDEA: XBRL DOCUMENT

Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Other comprehensive income from continuing operations, net of income taxes
Beginning of Year			$ 21,326
Other comprehensive income (loss)	$ 690	$ (2,207)	125	$ (2,285)
End of Year	20,896		20,896
Cumulative Foreign Currency Translation Adjustments
Other comprehensive income from continuing operations, net of income taxes
Beginning of Year	(4,512)	(3,643)	(4,829)	(2,924)
Impact of business dispositions				108
Other comprehensive income (loss) before reclassifications	89	(645)	406	(1,472)
Other comprehensive income (loss)	89	(645)	406	(1,472)
End of Year	(4,423)	(4,288)	(4,423)	(4,288)
Net Actuarial Losses and Prior Service Costs and Credits
Other comprehensive income from continuing operations, net of income taxes
Beginning of Year	(1,987)	(2,157)	(1,958)	(2,229)
Impact of business dispositions				19
Other comprehensive income (loss) before reclassifications			(62)
Amounts reclassified from accumulated other comprehensive income (loss)	15	26	48	79
Other comprehensive income (loss)	15	26	(14)	79
End of Year	(1,972)	(2,131)	(1,972)	(2,131)
Cumulative Unrealized Gains (Losses) on Marketable Equity Securities
Other comprehensive income from continuing operations, net of income taxes
Beginning of Year	(691)	696	65	1
Other comprehensive income (loss) before reclassifications	(362)	(1,596)	(1,118)	(763)
Amounts reclassified from accumulated other comprehensive income (loss)	975		975	(138)
Other comprehensive income (loss)	613	(1,596)	(143)	(901)
End of Year	(78)	(900)	(78)	(900)
Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
Other comprehensive income from continuing operations, net of income taxes
Beginning of Year	(33)	100	64	99
Other comprehensive income (loss) before reclassifications	(30)	41	(77)	89
Amounts reclassified from accumulated other comprehensive income (loss)	3	(33)	(47)	(80)
Other comprehensive income (loss)	(27)	8	(124)	9
End of Year	$ (60)	$ 108	$ (60)	$ 108

XML 49 R37.htm IDEA: XBRL DOCUMENT

Business Acquisitions (Details) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended
	Jan. 30, 2016	Feb. 29, 2016	Aug. 31, 2015	Sep. 30, 2016	Dec. 31, 2015
Allocation of the fair value
Goodwill, non-deductible				$ 7,812	$ 9,638
Maximum
Allocation of the fair value
Senior unsecured bridge term loan		$ 9,000
Bridge loan
Allocation of the fair value
Maturity period		364 days
Tendyne Holdings, Inc.
Business acquisitions
Cash paid for business acquisition			$ 225
Additional payments upon completion of certain regulatory milestones			150
Allocation of the fair value
Acquired intangible assets, non-deductible			220
Goodwill, non-deductible			142
Deferred tax assets and Other net assets			18
Deferred income taxes recorded at acquisition			(85)
Contingent consideration			$ 70
Alere Inc
Allocation of the fair value
Annual sales	$ 2,500
Share price (in dollars per share)	$ 56
Expected equity value	$ 5,800
Liabilities assumed	$ 2,500

XML 50 R38.htm IDEA: XBRL DOCUMENT

Business Acquisitions - St Jude Acquisition (Details) - St Jude Medical - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
	Apr. 27, 2016	Dec. 31, 2015	Oct. 18, 2016
Business acquisitions
Annual sales		$ 5,500
Share price (in dollars per share)	$ 46.75
Shares of stock (in shares)	0.8708
Weighted average share price	$ 40.74
Expected equity value (in dollars per share)	$ 82
Expected equity value	$ 24,000
Assumed debt	$ 5,400
Maturity period	364 days
Senior unsecured bridge term loan	$ 17,200
Supply Commitment \| Terumo
Business acquisitions
Purchase price for agreement to sell products			$ 1,120

XML 51 R39.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets (Details). - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Goodwill and intangible assets information
Goodwill	$ 7,812	$ 9,638
Purchase price allocation adjustments associated with acquisitions	0
Foreign currency translation adjustments	126
Amount of reduction of goodwill relating to impairments	0
Established Pharmaceutical Products
Goodwill and intangible assets information
Goodwill	3,000
Nutritional Products
Goodwill and intangible assets information
Goodwill	286
Diagnostic Products
Goodwill and intangible assets information
Goodwill	451
Vascular Products
Goodwill and intangible assets information
Goodwill	3,100
AMO \| Dispositions held for sale
Goodwill and intangible assets information
Goodwill moved to Non-current assets held for disposition	$ 2,000

XML 52 R40.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Goodwill and Intangible Assets
Gross amount of amortizable intangible assets	$ 10,500	$ 10,800
Accumulated amortization of intangible assets	6,100	5,700
Change in intangible assets due to foreign currency translation and other adjustments	72
Indefinite-lived intangible assets related to in-process research and development acquired in a business combination	325	$ 419
Estimated annual amortization expense, intangible assets, 2016	560
Estimated annual amortization expense, intangible assets, 2017	490
Estimated annual amortization expense, intangible assets, 2018	450
Estimated annual amortization expense, intangible assets, 2019	420
Estimated annual amortization expense, intangible assets, 2020	410
Non-reportable segment
Goodwill and Intangible Assets
Impairment charges for certain research and development assets	$ 59
Minimum
Goodwill and Intangible Assets
Average amortization period, intangible assets	2 years
Maximum
Goodwill and Intangible Assets
Average amortization period, intangible assets	20 years
Average
Goodwill and Intangible Assets
Average amortization period, intangible assets	13 years
Dispositions held for sale \| AMO
Goodwill and Intangible Assets
Net intangible assets moved to Non-current assets held for disposition	$ 533

XML 53 R41.htm IDEA: XBRL DOCUMENT

Restructuring Plans (Details) $ in Millions	9 Months Ended
Restructuring Plans (Details) $ in Millions	Sep. 30, 2016 USD ($)
Restructuring Plan 2016, 2015 and 2014
Restructuring reserve activity
Restructuring reserve, beginning balance of the period	$ 100
Restructuring charges	23
Payments and other adjustments	(47)
Restructuring reserve, ending balance of the period	76
Restructuring Plan 2016, 2015 And 2014
Restructuring costs
Accelerated depreciation and product transfer costs	2
Restructuring Plan 2016, 2015 And 2014 \| Cost of products sold
Restructuring reserve activity
Restructuring charges	7
Restructuring Plan 2016, 2015 And 2014 \| Selling, general and administrative expense
Restructuring reserve activity
Restructuring charges	16
Restructuring Plan 2013 to 2015
Restructuring reserve activity
Restructuring reserve, beginning balance of the period	88
Restructuring charges	12
Payments and other adjustments	(65)
Restructuring reserve, ending balance of the period	35
Restructuring Plan 2013 and Prior Years
Restructuring reserve activity
Restructuring reserve, beginning balance of the period	11
Payments and other adjustments	(6)
Restructuring reserve, ending balance of the period	$ 5

XML 54 R42.htm IDEA: XBRL DOCUMENT

Incentive Stock Programs (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2016 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award
Incentive stock programs, shares reserved for future grants	57,000,000
Total unrecognized compensation cost \| $	$ 237
Total unrecognized compensation cost, recognition period	3 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award
Grants in period, stock options (in shares)	7,699,301
Stock options outstanding, number of shares	36,376,374
Stock options outstanding, weighted-average remaining life	5 years 4 months 24 days
Stock options outstanding, weighted-average exercise price (in dollars per share) \| $ / shares	$ 34.01
Aggregate intrinsic value of options outstanding \| $	$ 328
Exercisable options, number of shares	23,861,634
Exercisable options, weighted-average remaining life	3 years 8 months 12 days
Exercisable options, weighted-average exercise price (in dollars per share) \| $ / shares	$ 30.36
Aggregate intrinsic value of options exercisable \| $	$ 294
Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award
Awards and units granted during period (in shares)	776,510
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award
Awards and units granted during period (in shares)	7,467,430

XML 55 R43.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures - Derivative Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Derivative instruments, notional amount and fair value
Fair Value - Assets	$ 361	$ 295
Fair Value - Liabilities	678	541
Designated as hedging instrument \| Short-term borrowings \| Net investment hedges
Derivative instruments, notional amount and fair value
Fair Value - Liabilities	522	439
Designated as hedging instrument \| Interest rate swaps \| Fair value hedges
Derivative instruments, notional amount and fair value
Gross notional amount of cash flow hedge instruments	4,000	4,000
Designated as hedging instrument \| Interest rate swaps \| Deferred income taxes and other assets \| Fair value hedges
Derivative instruments, notional amount and fair value
Fair Value - Assets	211	116
Designated as hedging instrument \| Foreign currency forward exchange contracts. \| Cash flow hedges
Derivative instruments, notional amount and fair value
Gross notional amount of cash flow hedge instruments	$ 2,900	2,400
Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold	12 months
Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold	18 months
Designated as hedging instrument \| Foreign currency forward exchange contracts. \| Prepaid expenses and other receivables
Derivative instruments, notional amount and fair value
Fair Value - Assets	$ 28	64
Designated as hedging instrument \| Foreign currency forward exchange contracts. \| Other accrued liabilities
Derivative instruments, notional amount and fair value
Fair Value - Liabilities	97	18
Not designated as hedging instrument \| Foreign currency forward exchange contracts.
Derivative instruments, notional amount and fair value
Gross notional amount of cash flow hedge instruments	15,500	14,000
Not designated as hedging instrument \| Foreign currency forward exchange contracts. \| Prepaid expenses and other receivables
Derivative instruments, notional amount and fair value
Fair Value - Assets	122	115
Not designated as hedging instrument \| Foreign currency forward exchange contracts. \| Other accrued liabilities
Derivative instruments, notional amount and fair value
Fair Value - Liabilities	$ 59	$ 84

XML 56 R44.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures - Derivative Instruments, Gain (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net investment hedges \| Designated as hedging instrument
Gain (loss) on derivatives
Gain (loss) Recognized in Other Comprehensive Income (loss)	$ (6)	$ (11)	$ (83)	$ 3
Interest rate swaps \| Fair value hedges \| Designated as hedging instrument \| Interest expense
Gain (loss) on derivatives
Income (expense) and Gain (loss) Reclassified into Income	(50)	85	95	71
Foreign currency forward exchange contracts. \| Not designated as hedging instrument \| Net foreign exchange loss (gain)
Gain (loss) on derivatives
Income (expense) and Gain (loss) Reclassified into Income	(5)	(9)	16	92
Foreign currency forward exchange contracts. \| Cash flow hedges \| Designated as hedging instrument \| Cost of products sold
Gain (loss) on derivatives
Gain (loss) Recognized in Other Comprehensive Income (loss)	(45)	41	(96)	89
Income (expense) and Gain (loss) Reclassified into Income	$ 5	$ 33	$ 59	$ 80

XML 57 R45.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures - Carrying Values And Fair Values Of Certain Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Fair value, asset and liability measures
Investments Securities	$ 2,997	$ 4,041
Foreign currency forward exchange contracts, receivable position	361	295
Foreign currency forward exchange contracts, (payable) position	(678)	(541)
Equity securities
Fair value, asset and liability measures
Investments Securities	2,946	4,014
Carrying value
Fair value, asset and liability measures
Total long-term debt	(5,979)	(5,874)
Foreign currency forward exchange contracts, receivable position	150	179
Foreign currency forward exchange contracts, (payable) position	(156)	(102)
Interest rate hedge contracts, receivable position	211	116
Carrying value \| Equity securities
Fair value, asset and liability measures
Investments Securities	2,946	4,014
Carrying value \| Other.
Fair value, asset and liability measures
Investments Securities	51	27
Fair value
Fair value, asset and liability measures
Total long-term debt	(6,665)	(6,337)
Foreign currency forward exchange contracts, receivable position	150	179
Foreign currency forward exchange contracts, (payable) position	(156)	(102)
Interest rate hedge contracts, receivable position	211	116
Fair value \| Equity securities
Fair value, asset and liability measures
Investments Securities	2,946	4,014
Fair value \| Other.
Fair value, asset and liability measures
Investments Securities	$ 55	$ 30

XML 58 R46.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures - Assets And Liabilities At Fair Value On A Recurring Basis (Details) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Fair value, asset and liability measures
Fair Value - Assets	$ 361	$ 295
Fair Value - Liabilities	678	541
Recurring
Fair value, asset and liability measures
Equity securities	2,675	3,780
Interest rate swap derivative financial instruments, assets	211	116
Total Assets	3,036	4,075
Fair value of hedged long-term debt	4,238	4,135
Contingent consideration related to business combinations	163	173
Total Liabilities	4,557	4,410
Recurring \| Foreign currency forward exchange contracts
Fair value, asset and liability measures
Fair Value - Assets	150	179
Fair Value - Liabilities	156	102
Recurring \| Quoted Prices in Active Markets
Fair value, asset and liability measures
Equity securities	2,675	3,780
Total Assets	2,675	3,780
Recurring \| Significant Other Observable Inputs
Fair value, asset and liability measures
Interest rate swap derivative financial instruments, assets	211	116
Total Assets	361	295
Fair value of hedged long-term debt	4,238	4,135
Total Liabilities	4,394	4,237
Recurring \| Significant Other Observable Inputs \| Foreign currency forward exchange contracts
Fair value, asset and liability measures
Fair Value - Assets	150	179
Fair Value - Liabilities	156	102
Recurring \| Significant Unobservable Inputs
Fair value, asset and liability measures
Contingent consideration related to business combinations	163	173
Total Liabilities	$ 163	$ 173

XML 59 R47.htm IDEA: XBRL DOCUMENT

Litigation and Environmental Matters (Details) $ in Millions	Sep. 30, 2016 USD ($)
Loss Contingencies
Maximum expected cleanup exposure for individual site	$ 4
Maximum expected cleanup exposure in aggregate	10
Other legal proceedings and environmental exposures
Loss Contingencies
Recorded reserve balance for legal proceedings and exposures	45
Other legal proceedings and environmental exposures \| Minimum
Loss Contingencies
Other legal proceedings or environmental exposure	40
Other legal proceedings and environmental exposures \| Maximum
Loss Contingencies
Other legal proceedings or environmental exposure	$ 45

XML 60 R48.htm IDEA: XBRL DOCUMENT

Post-Employment Benefits (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Post-Employment Benefits (Details) - USD ($) $ in Millions	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Defined Benefit Plans
Defined benefit plan net periodic benefit cost
Service cost - benefits earned during the period	$ 66	$ 80	$ 200	$ 230
Interest cost on projected benefit obligations	72	78	218	234
Expected return on plan assets	(142)	(128)	(426)	(385)
Actuarial loss, net	34	47	97	136
Net cost	30	77	89	215
Net amortization of:
Company contributions			540	551
Defined Benefit Plans \| Discontinued operations
Defined benefit plan net periodic benefit cost
Net cost				1
Defined Benefit Plans \| Continuing operations
Defined benefit plan net periodic benefit cost
Net cost	30	77	89	214
Medical and Dental Plans
Defined benefit plan net periodic benefit cost
Service cost - benefits earned during the period	7	9	20	24
Interest cost on projected benefit obligations	11	14	33	39
Expected return on plan assets	(9)	(10)	(26)	(29)
Actuarial loss, net	4	8	13	18
Prior service cost (credit)	(12)	(12)	(34)	(36)
Net cost	1	9	6	16
Net amortization of:
Company contributions			9	24
Medical and Dental Plans \| Continuing operations
Defined benefit plan net periodic benefit cost
Net cost	$ 1	$ 9	$ 6	$ 16

XML 61 R49.htm IDEA: XBRL DOCUMENT

Taxes on Earnings (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Taxes on Earnings (Details) - USD ($) $ in Millions	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Taxes on Earnings
Favorable resolution of various tax positions and other unusual provision items			$ 250
Decrease in gross unrecognized tax benefits			546
Income Tax Benefit	$ 23	$ (26)	289	$ (21)
Tax cost related to the disposal of shares				71
Non-cash impact of tax expense associated with the gain on the sale of businesses				1,100
Minimum
Taxes on Earnings
Decrease reasonably possible in gross unrecognized tax benefits	100		100
Maximum
Taxes on Earnings
Decrease reasonably possible in gross unrecognized tax benefits	200		200
AbbVie
Taxes on Earnings
Income Tax Benefit	$ 19	$ (27)	$ 282	(10)
Discontinued operations
Taxes on Earnings
Non-cash impact of tax expense associated with the gain on the sale of businesses				667
Discontinued operations \| AbbVie
Taxes on Earnings
Decrease in gross unrecognized tax benefits				16
Income Tax Benefit				$ (10)

XML 62 R50.htm IDEA: XBRL DOCUMENT

Segment Information (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
Segment Information (Details) - USD ($) $ in Millions	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information
Net Sales to External Customers		$ 5,302	$ 5,150	$ 15,520	$ 15,217
Operating Earnings		897	713	2,237	2,052
Amortization of intangible assets		(140)	(151)	(429)	(458)
Earnings (loss) from continuing operations before taxes		(179)	714	$ 538	2,353
Annual share-based awards recognized in first quarter (as a percent)				50.00%
Mylan N.V. equity investment adjustment	$ 947			$ 947
Foreign Currency Transaction Loss, before Tax				481
Venezuela
Segment Reporting Information
Foreign Currency Transaction Loss, before Tax				481
Other
Segment Reporting Information
Net Sales to External Customers		614	572	1,742	1,689
Total Reportable Segments
Segment Reporting Information
Net Sales to External Customers		4,688	4,578	13,778	13,528
Operating Earnings		1,199	1,182	3,341	3,404
Total Reportable Segments \| Established Pharmaceutical Products
Segment Reporting Information
Net Sales to External Customers		1,012	961	2,880	2,835
Operating Earnings		211	177	551	516
Total Reportable Segments \| Nutritional Products
Segment Reporting Information
Net Sales to External Customers		1,755	1,789	5,166	5,175
Operating Earnings		438	459	1,148	1,198
Total Reportable Segments \| Diagnostic Products
Segment Reporting Information
Net Sales to External Customers		1,213	1,156	3,557	3,426
Operating Earnings		301	307	856	887
Total Reportable Segments \| Vascular Products
Segment Reporting Information
Net Sales to External Customers		708	672	2,175	2,092
Operating Earnings		249	239	786	803
Corporate functions
Segment Reporting Information
Corporate functions and benefit plans costs		(107)	(109)	(282)	(330)
Reconciling items
Segment Reporting Information
Non-reportable segments		105	76	155	193
Net interest expense		(95)	(16)	(203)	(49)
Share-based compensation		(49)	(43)	(263)	(248)
Amortization of intangible assets		(140)	(151)	(429)	(458)
Other, net		$ (1,092)	$ (225)	$ (1,781)	$ (159)

EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
&PO=V]R:W-H965T&UL4$L! A0#% @ =H-C24>R9W75 P GA, !D M ( !>90 'AL+W=O&PO=V]R M:W-H965T3! 4 %8< M 9 " ;"; !X;"]W;W)K&UL M4$L! A0#% @ =H-C26U"GW.J00 K3T! !0 ( !ZZ K 'AL+W-H87)E9%-T&UL4$L%!@ [ #L #Q ,?B $! end XML 64 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 241 278 1 false 77 0 false 4 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.abbott.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Statement of Earnings Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings Condensed Consolidated Statement of Earnings Statements 2 false false R3.htm 00200 - Statement - Condensed Consolidated Statement of Comprehensive Income Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome Condensed Consolidated Statement of Comprehensive Income Statements 3 false false R4.htm 00205 - Statement - Condensed Consolidated Statement of Comprehensive Income (Parenthetical) Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncomeParenthetical Condensed Consolidated Statement of Comprehensive Income (Parenthetical) Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Balance Sheet Sheet http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet Condensed Consolidated Balance Sheet Statements 5 false false R6.htm 00305 - Statement - Condensed Consolidated Balance Sheet (Parenthetical) Sheet http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheetParenthetical Condensed Consolidated Balance Sheet (Parenthetical) Statements 6 false false R7.htm 00400 - Statement - Condensed Consolidated Statement of Cash Flows Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows Condensed Consolidated Statement of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - Basis of Presentation Sheet http://www.abbott.com/role/DisclosureBasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 10201 - Disclosure - Discontinued Operations Sheet http://www.abbott.com/role/DisclosureDiscontinuedOperations Discontinued Operations Notes 9 false false R10.htm 10301 - Disclosure - Assets and Liabilities Held for Disposition Sheet http://www.abbott.com/role/DisclosureAssetsAndLiabilitiesHeldForDisposition Assets and Liabilities Held for Disposition Notes 10 false false R11.htm 10401 - Disclosure - Supplemental Financial Information Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformation Supplemental Financial Information Notes 11 false false R12.htm 10501 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) Sheet http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLoss Changes in Accumulated Other Comprehensive Income (Loss) Notes 12 false false R13.htm 10601 - Disclosure - Business Acquisitions Sheet http://www.abbott.com/role/DisclosureBusinessAcquisitions Business Acquisitions Notes 13 false false R14.htm 10701 - Disclosure - Goodwill and Intangible Assets Sheet http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 14 false false R15.htm 10801 - Disclosure - Restructuring Plans Sheet http://www.abbott.com/role/DisclosureRestructuringPlans Restructuring Plans Notes 15 false false R16.htm 10901 - Disclosure - Incentive Stock Programs Sheet http://www.abbott.com/role/DisclosureIncentiveStockPrograms Incentive Stock Programs Notes 16 false false R17.htm 11001 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasures Financial Instruments, Derivatives and Fair Value Measures Notes 17 false false R18.htm 11101 - Disclosure - Litigation and Environmental Matters Sheet http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMatters Litigation and Environmental Matters Notes 18 false false R19.htm 11201 - Disclosure - Post-Employment Benefits Sheet http://www.abbott.com/role/DisclosurePostEmploymentBenefits Post-Employment Benefits Notes 19 false false R20.htm 11301 - Disclosure - Taxes on Earnings Sheet http://www.abbott.com/role/DisclosureTaxesOnEarnings Taxes on Earnings Notes 20 false false R21.htm 11401 - Disclosure - Segment Information Sheet http://www.abbott.com/role/DisclosureSegmentInformation Segment Information Notes 21 false false R22.htm 30203 - Disclosure - Discontinued Operations (Tables) Sheet http://www.abbott.com/role/DisclosureDiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.abbott.com/role/DisclosureDiscontinuedOperations 22 false false R23.htm 30303 - Disclosure - Assets and Liabilities Held for Disposition (Tables) Sheet http://www.abbott.com/role/DisclosureAssetsAndLiabilitiesHeldForDispositionTables Assets and Liabilities Held for Disposition (Tables) Tables http://www.abbott.com/role/DisclosureAssetsAndLiabilitiesHeldForDisposition 23 false false R24.htm 30403 - Disclosure - Supplemental Financial Information (Tables) Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformationTables Supplemental Financial Information (Tables) Tables http://www.abbott.com/role/DisclosureSupplementalFinancialInformation 24 false false R25.htm 30503 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossTables Changes in Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLoss 25 false false R26.htm 30803 - Disclosure - Restructuring Plans (Tables) Sheet http://www.abbott.com/role/DisclosureRestructuringPlansTables Restructuring Plans (Tables) Tables http://www.abbott.com/role/DisclosureRestructuringPlans 26 false false R27.htm 30903 - Disclosure - Incentive Stock Programs (Tables) Sheet http://www.abbott.com/role/DisclosureIncentiveStockProgramsTables Incentive Stock Programs (Tables) Tables http://www.abbott.com/role/DisclosureIncentiveStockPrograms 27 false false R28.htm 31003 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresTables Financial Instruments, Derivatives and Fair Value Measures (Tables) Tables http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasures 28 false false R29.htm 31203 - Disclosure - Post-Employment Benefits (Tables) Sheet http://www.abbott.com/role/DisclosurePostEmploymentBenefitsTables Post-Employment Benefits (Tables) Tables http://www.abbott.com/role/DisclosurePostEmploymentBenefits 29 false false R30.htm 31403 - Disclosure - Segment Information (Tables) Sheet http://www.abbott.com/role/DisclosureSegmentInformationTables Segment Information (Tables) Tables http://www.abbott.com/role/DisclosureSegmentInformation 30 false false R31.htm 40201 - Disclosure - Discontinued Operations - (Details) Sheet http://www.abbott.com/role/DisclosureDiscontinuedOperationsDetails Discontinued Operations - (Details) Details http://www.abbott.com/role/DisclosureDiscontinuedOperationsTables 31 false false R32.htm 40202 - Disclosure - Discontinued Operations - AbbVie Separation (Details) Sheet http://www.abbott.com/role/DisclosureDiscontinuedOperationsAbbvieSeparationDetails Discontinued Operations - AbbVie Separation (Details) Details 32 false false R33.htm 40301 - Disclosure - Assets and Liabilities Held for Disposition (Details) Sheet http://www.abbott.com/role/DisclosureAssetsAndLiabilitiesHeldForDispositionDetails Assets and Liabilities Held for Disposition (Details) Details http://www.abbott.com/role/DisclosureAssetsAndLiabilitiesHeldForDispositionTables 33 false false R34.htm 40302 - Disclosure - Discontinued Operations - Assets And Liabilities Held For Disposition (Details) Sheet http://www.abbott.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesHeldForDispositionDetails Discontinued Operations - Assets And Liabilities Held For Disposition (Details) Details 34 false false R35.htm 40401 - Disclosure - Supplemental Financial Information (Details). Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformationDetails Supplemental Financial Information (Details). Details http://www.abbott.com/role/DisclosureSupplementalFinancialInformationTables 35 false false R36.htm 40501 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails Changes in Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossTables 36 false false R37.htm 40601 - Disclosure - Business Acquisitions (Details) Sheet http://www.abbott.com/role/DisclosureBusinessAcquisitionsDetails Business Acquisitions (Details) Details http://www.abbott.com/role/DisclosureBusinessAcquisitions 37 false false R38.htm 40602 - Disclosure - Business Acquisitions - St Jude Acquisition (Details) Sheet http://www.abbott.com/role/DisclosureBusinessAcquisitionsStJudeAcquisitionDetails Business Acquisitions - St Jude Acquisition (Details) Details 38 false false R39.htm 40701 - Disclosure - Goodwill and Intangible Assets (Details). Sheet http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsDetails Goodwill and Intangible Assets (Details). Details http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssets 39 false false R40.htm 40702 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details) Sheet http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails Goodwill and Intangible Assets - Intangible Assets (Details) Details 40 false false R41.htm 40801 - Disclosure - Restructuring Plans (Details) Sheet http://www.abbott.com/role/DisclosureRestructuringPlansDetails Restructuring Plans (Details) Details http://www.abbott.com/role/DisclosureRestructuringPlansTables 41 false false R42.htm 40901 - Disclosure - Incentive Stock Programs (Details) Sheet http://www.abbott.com/role/DisclosureIncentiveStockProgramsDetails Incentive Stock Programs (Details) Details http://www.abbott.com/role/DisclosureIncentiveStockProgramsTables 42 false false R43.htm 41001 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Derivative Information (Details) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresDerivativeInformationDetails Financial Instruments, Derivatives and Fair Value Measures - Derivative Information (Details) Details 43 false false R44.htm 41002 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Derivative Instruments, Gain (Loss) (Details) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresDerivativeInstrumentsGainLossDetails Financial Instruments, Derivatives and Fair Value Measures - Derivative Instruments, Gain (Loss) (Details) Details 44 false false R45.htm 41003 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Values And Fair Values Of Certain Financial Instruments (Details) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValuesAndFairValuesOfCertainFinancialInstrumentsDetails Financial Instruments, Derivatives and Fair Value Measures - Carrying Values And Fair Values Of Certain Financial Instruments (Details) Details 45 false false R46.htm 41004 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Assets And Liabilities At Fair Value On A Recurring Basis (Details) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetails Financial Instruments, Derivatives and Fair Value Measures - Assets And Liabilities At Fair Value On A Recurring Basis (Details) Details 46 false false R47.htm 41101 - Disclosure - Litigation and Environmental Matters (Details) Sheet http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails Litigation and Environmental Matters (Details) Details http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMatters 47 false false R48.htm 41201 - Disclosure - Post-Employment Benefits (Details) Sheet http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails Post-Employment Benefits (Details) Details http://www.abbott.com/role/DisclosurePostEmploymentBenefitsTables 48 false false R49.htm 41301 - Disclosure - Taxes on Earnings (Details) Sheet http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails Taxes on Earnings (Details) Details http://www.abbott.com/role/DisclosureTaxesOnEarnings 49 false false R50.htm 41401 - Disclosure - Segment Information (Details) Sheet http://www.abbott.com/role/DisclosureSegmentInformationDetails Segment Information (Details) Details http://www.abbott.com/role/DisclosureSegmentInformationTables 50 false false All Reports Book All Reports abt-20160930.xml abt-20160930.xsd abt-20160930_cal.xml abt-20160930_def.xml abt-20160930_lab.xml abt-20160930_pre.xml true true ZIP 69 0001104659-16-154583-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-16-154583-xbrl.zip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